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ABSTRACT 
The Impact of Diffuse Large B-Cell Lymphoma on Primary Care and Costs of Chronic 
Conditions in Elderly Medicare Beneficiaries 
 
Rahul Garg 
 
 Diffuse Large B-Cell Lymphoma (DLBCL) is an aggressive form of Non-Hodgkin’s 
lymphoma with a median age of diagnosis of 67 years. The intensive treatment of DLBCL can 
negatively influence elderly patients’ preventive and chronic care, which can increase the costs 
of different chronic conditions. DLBCL diagnosis and treatment can affect patients’ visits to 
their primary care providers (PCPs) and other specialists, which are important for patients’ 
preventive screenings and chronic care. Further, having DLBCL increases the risk for breast 
cancer, and DLBCL treatment is associated with cardiotoxicity and increases the risk of 
osteoporosis and fractures. Thus, mammography and bone mineral density testing (BDT) are 
critical areas of screening for individuals with DLBCL, and a change in visits to PCPs can affect 
preventive and chronic care. Along with these challenges to care quality in DLBCL patients, the 
costs of different chronic conditions may increase. Currently, there is a dearth of studies that 
have examined visits to PCPs and specialists, preventive screenings, and costs of chronic 
conditions among DLBCL patients as compared to individuals with no cancer. We conducted 
this study to reduce this knowledge gap and to provide actionable strategies to improve the 
preventive care and reduce the costs of DLBCL patients. The three specific aims of this study 
were to: 1) analyze the impact of DLBCL on visits to PCPs and specialists over a three-year 
period of DLBCL diagnosis, treatment, and follow-up; 2) examine the receipt of mammography 
and BDT by female DLBCL patients during two years after DLBCL diagnosis; and 3) examine 
the costs of common chronic conditions and total cost over a three-year period of DLBCL 
diagnosis, treatment, and follow-up among fee-for-service elderly Medicare beneficiaries with 
  
newly diagnosed DLBCL as compared to Medicare beneficiaries without cancer. We used a 
retrospective longitudinal study design for aim 1 and aim 3; and a cross-sectional design for aim 
2 of this study. We used Surveillance, Epidemiology and End Results (SEER) program (2002-
2013) data linked with Medicare administrative claims and the Area Health Resource Files. In 
the first aim, DLBCL patients (n = 5,455) were more likely to visit PCPs (AOR [95%CI]: 1.25 
[1.18, 1.31]) and had a greater number of visits to PCPs (β, SE: 0.384, -0.014) than non-cancer 
patients (n = 14,770). Further, DLBCL patients were more likely to have any visit to a 
cardiologist (AOR [95%CI]: 1.40 [1.32, 1.47]), endocrinologist (1.43, [1.21, 1.70]), and 
pulmonologist (1.51 [1.36, 1.67]) than non-cancer patients. Among DLBCL patients, the number 
of PCP visits markedly increased during the treatment period compared to the baseline period (β, 
SE: 0.491, -0.028) and then decreased to baseline levels (-0.464, -0.022). In the second aim, 
although DLBCL and its treatment increase the risk of breast cancer and bone density loss, 
mammography and BDT did not differ between women with DLBCL (mammography: 59.8%, 
BDT: 18.5%) and no cancer (mammography: 60.2%, BDT: 19.6%; p > .05). After adjusting for 
PCP visits, DLBCL patients were less likely to have mammography (AOR [95%CI]: 0.82 [0.71, 
0.94]) and BDT (0.80 [0.71, 0.90]) than non-cancer patients. Further, those with more primary 
care physician visits were more likely to have mammography (1.62 [1.48, 1.77]) and BDT (1.60 
[1.50, 1.71]). In the third aim, the net total cost of DLBCL patients increased substantially during 
the treatment period ($60,746.1). DLBCL patients had significantly higher cost of heart 
conditions but lower costs of hypertension, asthma/chronic obstructive pulmonary disease, any 
mental illness, and diabetes than non-cancer patients (all p< .001). To summarize, our study 
found that the visits to PCPs and specialists were much higher for DLBCL than non-cancer 
patients, which drastically increased during the DLBCL treatment period for chronic care. 
  
Treatment adverse effects and more frequent contact with healthcare system may have increased 
the visits to PCPs and specialists. Female DLBCL patients received lower preventive care, which 
may be due to prioritization of DLBCL treatment. There is a need to increase the 
recommendations for mammography and BDT to reduce the morbidity and mortality from breast 
cancer and fractures. DLBCL treatment cardiotoxicity may have increased the cost of heart 
conditions, while suboptimal care may have reduced the short term costs of other common 
chronic conditions. Interventions are needed to increase the preventive and chronic care among 
elderly DLBCL patients.  
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Chapter 1: Introduction 
1.1 Background 
Diffuse Large B-Cell Lymphoma (DLBCL) is an aggressive and the most common 
subtype of Non-Hodgkin’s Lymphoma, accounting for about 30-40% of all newly diagnosed 
cases.1 Newly diagnosed DLBCL requires intensive treatment with chemo-immunotherapy, 
radiotherapy, or stem cell transplant.2,3 Due to these treatments, many DLBCL cases (~ 60%) are 
cured and DLBCL patients have a 5-year survival rate of 60.5%.1,4 However, aggressive 
treatment of DLBCL can lead to many adverse consequences5 such as secondary cancers,6 post-
traumatic stress,7 and poor quality of life.8 Further, most DLBCL patients are above 65 years of 
age,910 who have at least one (82.0%) or two or more (67.3%) chronic physical and mental 
conditions (multimorbidity).11,12 The National Cancer Institute (NCI) comorbidity score, which 
measures the number and severity of 15 non-cancer comorbidities, ranged from 1-3 for a 
majority of DLBCL patients.3  
The treatment side effects and presence of multiple chronic conditions require regular 
visits to multiple providers for chronic and preventive care. The role of multiple provider 
specialties in providing care to cancer patients has been emphasized by the Institute of Medicine 
(IOM) in its report on delivering high-quality cancer care.13 These different providers include 
oncologists (e.g., hematology, medical oncology, surgical oncology, and radiation oncology), 
primary care physicians (PCPs, e.g., general internal medicine, family medicine), other physician 
specialties (e.g., endocrinology, pulmonology, and ophthalmology - hereafter referred to as 
“other medical specialists”), nurses, and caregivers.13 A diagnosis of DLBCL can affect patients’ 
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visits to different provider specialties, thereby negatively affecting their chronic and preventive 
care.14 
Less chronic and preventive care can decrease the short term costs but increase the long 
term costs of chronic conditions, which has not been previously investigated. Elderly individuals 
with multiple chronic conditions bear a significant cost burden due to these multiple illnesses, 
which can be disproportionately affected by a diagnosis of cancer. DLBCL treatment increases 
the risk of breast cancer6,15 and osteoporosis16 and can increase the severity of other chronic 
conditions leading to higher costs. Conversely, prioritization of DLBCL treatment can eclipse 
patients’ chronic care and can reduce the short term costs of certain chronic conditions. There is 
a lack of research on how DLBCL diagnosis affects patients’ visits to different provider 
specialties, their preventive care, and the resulting costs of chronic conditions among elderly 
Medicare beneficiaries with DLBCL. Therefore, the overall goal of this dissertation is to analyze 
the impact of newly diagnosed DLBCL on visits to PCPs and specialists, preventive care, and 
costs of chronic conditions among Medicare beneficiaries with DLBCL as compared to 
beneficiaries without cancer.  
The dissertation is organized in five chapters. Chapter 1 briefly describes the 
epidemiology and treatment of DLBCL, need for this study, data sources, and the theoretical 
framework used for this study. Chapter 2 focuses on the change in visits to PCPs and other 
medical specialists over a 3-year period of DLBCL diagnosis, treatment, and follow-up among 
DLBCL patients as compared to those without cancer. Chapter 3 describes the receipt of 
mammography and bone mineral density testing (BDT) among women with DLBCL as 
compared to women without cancer. Chapter 4 highlights the impact of DLBCL on the costs of 
common chronic conditions and total cost before DLBCL diagnosis, during DLBCL treatment, 
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and at follow-up periods among DLBCL patients as compared to those without cancer. Finally, 
chapter 5 summarizes the findings from chapter 2, 3, and 4 and includes the implications and 
recommendations for future research. Chapter 5 also consists of the limitations and strengths of 
this study.  
1.1.1 Epidemiology of DLBCL  
 Non-Hodgkin’s Lymphoma (NHL) is the most prevalent hematologic cancer in the US 
with 72,240 new cases diagnosed in 2017.17 DLBCL is the most common subtype of NHL, 
accounting for about one-third of NHL cases.1 The incidence of DLBCL is approximately 7 
cases per 100,000 individuals in the United States (US).18 Similar to most other subtypes of 
NHL, DLBCL is more prevalent in males (55%) than females. The incidence of DLBCL 
increases with age, with the median age of diagnosis being 67 years.9 However, African 
Americans are more likely to be diagnosed at <60 years of age (65%) than Whites (37%).19 Most 
DLBCL cases with localized disease and approximately half of those with advanced stage 
disease are cured by treatment, which leads to a moderate five-year survival rate of 60.5%.3 The 
survival rates have been found to be better for women (61%) than men (58%) and for Whites 
(60%) than African Americans (50%).19 Age at diagnosis >60 years, African American race, 
male sex, and advanced stage are associated with worse survival among DLBCL patients.19  
1.1.2 Treatment of DLBCL 
 The overall treatment period of DLBCL among elderly patients lasts for approximately 
six months from the date of DLBCL diagnosis.3 The treatment pattern for elderly patients with 
DLBCL includes chemo-immunotherapy (49%), chemotherapy only (23%), immunotherapy only 
(5%), or no treatment (23%) depending upon the stage of cancer and patient’s age.3 About 30-
40% of DLBCL patients present with limited stage (Ann Arbor stage I or II) disease.19 These 
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patients are usually treated with chemo-immunotherapy (3-6 cycles) using R-CHOP 
(cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab) with or without 
radiotherapy.3,20 Advanced stage DLBCL (60-70% cases) are given six cycles of R-CHOP or are 
recommended to be enrolled in a clinical trial. Radiotherapy to treat initially bulky disease (neo-
adjuvant chemotherapy) may also be employed for advanced DLBCL. If responsive, the patients 
are observed for disease progression with positron emission tomography/computed tomography 
(PET-CT) scan. All refractory or relapsed cases are considered for high dose chemotherapy with 
either autologous (patient’s) or allogeneic (someone else’s) stem cell transplant.20  
1.1.3 Visits to PCPs and Other Medical Specialists by DLBCL Patients 
 The adverse sequelae of DLBCL treatments and presence of multimorbidity in elderly 
DLBCL patients call for regular visits to PCPs and other medical specialists during and after the 
DLBCL treatment period. The patient’s PCP or other medical specialist might have a better 
knowledge of patient’s pre-existing chronic conditions, and they may be more effective in 
providing care for his/her chronic conditions. Other important roles of PCPs and other medical 
specialists for cancer patients include helping with treatment decisions, providing psychosocial 
support, and continuing preventive and chronic care.21 The IOM has emphasized the role of 
multiple providers and caregivers in providing high-quality cancer care during and after the 
cancer treatment period.13  
 Although physicians trained in family medicine or general internal medicine typically 
serve as PCPs, other medical specialists such as cardiologists, pulmonologists, or 
endocrinologists, assume an important role in providing health care to elderly individuals, due to 
the variety of chronic diseases that may be present (e.g., heart disease, chronic obstructive 
pulmonary disease, diabetes). Regular visits to PCPs and other medical specialists are 
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recommended for elderly individuals with chronic physical and mental conditions, which should 
not be interrupted during the DLBCL treatment and follow-up periods.22,23 However, there is a 
lack of studies on the impact of DLBCL diagnosis and treatment on the visits to PCPs and other 
medical specialists. 
1.1.4 Preventive Care of DLBCL Patients 
As outlined by the US Preventive Services Task Force (USPSTF), clinical preventive 
services for elderly individuals include a wide range of screenings for chronic diseases and 
immunizations24 (Table 1.1). Despite being covered by Medicare, less than half of elderly above 
65 years of age have been found to be up-to-date with recommended clinical preventive 
services.25 Receipt of preventive services, specifically mammography and BDT, is critical for 
women with DLBCL because of their heightened risk of breast cancer and osteoporosis.5,6,15,16 
Timely mammography screening and BDT can lead to early diagnosis of breast cancer and can 
reduce the risk of fractures in female DLBCL patients.26,27 Hence, it is important to assess the 
receipt of mammography and BDT among elderly women with newly diagnosed DLBCL as 
compared to women without cancer.  
Table 1.1 Selected Preventive Care Services for Adults over 65 years of Age 
U.S. Preventive Services Task Force Screening Recommendations 
1. Screening for Breast Cancer: Using Film Mammography 
Individualize decision to begin biennial screening according to the patient’s circumstances and 
values - Women aged 40-49 years. 
Biennial screening for women aged 50-74 years. 
Women aged ≥75 years - Evidence of benefit is lacking. 
2. Screening for Prostate Cancer 
Adult males - Do not use prostate-specific antigen (PSA)-based screening for prostate cancer 
(2012). 
In 2008, the USPSTF had recommended against PSA-based screening for men 75 years and 
older in 2008.  
3. Screening for Osteoporosis using dual-energy X-ray absorptiometry of the hip and lumbar 
spine.  
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Evidence is lacking about optimal intervals for repeated screening. 
Women age ≥65 years without previous known fractures or secondary causes of osteoporosis. 
Men without previous known fractures or secondary causes of osteoporosis – No 
recommendation. 
Advisory Committee on Immunization Practices–Recommended Immunizations 
4. Annual vaccination for Influenza - All adults 
 
The receipt of screening and preventive health services has been found to vary by the 
type of provider seen. Breast cancer patients with outpatient visits to a gynecologist or a PCP 
were found more likely to undergo mammograms.28 A study by Earle et al. found that the breast 
cancer patients who visited oncologists were more likely to receive mammography while those 
who visited a PCP were more likely to receive non-cancer related preventive services such as flu 
vaccine, lipid testing, and bone densitometry.29 Similarly, colorectal cancer patients who visited 
both PCP and oncologist were more likely to receive appropriate follow-up care for heart failure, 
diabetes care, and other preventive services.30-33 Although existing studies have examined the 
receipt of preventive care services in patients with breast and colorectal cancer, there is a lack of 
research on the association of PCP visits with preventive care of patients with DLBCL. 
1.1.5 Costs of Chronic Conditions for DLBCL Patients 
Medicare beneficiaries with multiple chronic conditions bear a disproportionate burden of 
costs of care.11 For example, 36% of Medicare Part A enrollees have >2 chronic conditions; 
however these enrollees account for 86% of total Part A expenditures.34 Similarly, 41% of 
Medicare Part B enrollees have >2 chronic conditions; but these enrollees account for 
approximately 70% of Part B payments.34 The cost burden of chronic conditions can be 
significantly increased by the diagnosis of DLBCL, which increases the risk and severity of 
certain chronic conditions. DLBCL patients are more likely to have osteoporosis and fractures 
due to chemotherapy and stem cell transplant.16,35,36 Also, the cardiotoxicity of chemotherapy 
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can worsen heart conditions, leading to an increase in costs of these conditions.37 However, the 
prioritization of cancer care can reduce the care provided for chronic conditions. For example, 
patients with colorectal cancer received lower care for heart conditions, diabetes, and Chronic 
Obstructive Pulmonary Disease (COPD),38,39 which can decrease the short term cost of these 
conditions. There is a paucity of studies that have investigated the cost of chronic conditions 
among cancer survivors as compared to those without cancer. Also, evidence is lacking on the 
change in cost of chronic conditions before cancer diagnosis, during cancer treatment, and at 
follow-up periods. 
Cost estimates of chronic conditions at different phases of cancer care are critical for 
resource allocation and setting benchmarks for cost reduction, as supported by the ‘Oncology 
Care Model, a new payment and delivery model from the Center for Medicare & Medicaid 
Innovation, which aims to increase the quality while reducing the cost of cancer care.40 Our 
study will examine the cost of specific chronic conditions and total costs of care, which will 
assist in implementing these innovative models of cancer care. 
1.2 Specific Aims 
The specific aims of this dissertation are as follows: 
Specific Aim 1. To examine the impact of DLBCL diagnosis on the visits to PCPs and, among 
those with chronic conditions, visits to other medical specialists among Medicare beneficiaries 
with DLBCL as compared to beneficiaries without cancer.   
 
 Objective 1.1: To examine the impact of DLBCL diagnosis on the visits to PCPs and 
other medical specialists among elderly Medicare beneficiaries >66 years of age with 
DLBCL as compared to beneficiaries without cancer.   
 
 Objective 1.2: To examine the change in visits to PCPs and other medical specialists 
before cancer diagnosis, during cancer treatment, and at follow-up periods among elderly 
Medicare beneficiaries >66 years of age with DLBCL as compared to beneficiaries 
without cancer.   
 
 8 
 
Specific Aim 2. To examine the receipt of mammography and BDT by female Medicare 
beneficiaries with DLBCL as compared to female beneficiaries without cancer.  
 
 Objective 2.1: To investigate the receipt of mammography and the association of PCP 
visits with mammography rates among female Medicare beneficiaries with DLBCL 
between 66 and 74 years of age as compared to those without cancer.  
 
 Objective 2.2: To investigate the receipt of BDT and the association of PCP visits with 
BDT rates among female Medicare beneficiaries with DLBCL >66 years of age as 
compared to those without cancer. 
 
Specific Aim 3. To evaluate the impact of DLBCL on the costs of common chronic conditions 
and total costs among elderly Medicare beneficiaries with DLBCL as compared to those without 
cancer. 
 
 Objective 3.1: To evaluate the change in costs of specific chronic conditions before 
cancer diagnosis, during cancer treatment, and at follow-up periods among Medicare 
beneficiaries with DLBCL as compared to those without cancer.  
 
 Objective 3.2: To evaluate the change in total costs before cancer diagnosis, during 
cancer treatment, and at follow-up periods among Medicare beneficiaries with DLBCL as 
compared to those without cancer.  
 
1.3 Study Hypotheses 
Aim 1 A previous study among breast cancer patients found that face-to-face visits with PCPs 
increased during the active treatment phase as compared to the period before cancer diagnosis.41 
Further, visits to PCPs by colorectal patients have been found to increase during the follow-up 
period after the cancer treatment is over, as compared to the pre-treatment period.42,43 Based on 
the results of these studies, we hypothesized that visits to PCPs and other medical specialists will 
increase during both the cancer treatment and follow-up periods as compared to the baseline 
period because cancer patients may have higher healthcare needs during the treatment period.  
Aim 2 Cancer patients have been found to be more likely to have preventive screenings than 
non-cancer patients. For example, breast cancer patients were more likely to receive 
mammography (74.0%) and BDT (8.3%) than patients without cancer (41.0% and 6.8%, 
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respectively).29 Similarly, colorectal cancer patients were more likely to receive a mammogram 
(49.8%) than non-cancer patients (47.4%).33 Hence, we hypothesized that women with DLBCL 
will be more likely to receive mammography and BDT than women without cancer.  
 Women cancer patients with higher visits to PCPs have been found to receive more 
preventive screenings.28,29,32 For example, breast cancer patients with more visits to PCPs were 
twice as likely to receive mammography28 and colorectal patients with more PCP visits were 
twice as likely to receive BDT.31 Hence, we hypothesized that patients with higher visits to PCPs 
will be more likely to receive mammography and BDT. 
Aim 3 Chemotherapy can worsen heart conditions in DLBCL patients.37 Also, stem cell 
transplant and chemotherapy can cause osteoporosis and fractures in DLBCL patients.16 Hence, 
for aim 3 we hypothesized that the cost of heart conditions, osteoporosis, and arthritis will 
increase during cancer treatment and short follow-up among DLBCL patients. According to 
previous studies, colorectal patients received lower care for diabetes and asthma/COPD.38 We 
hypothesized that due to lower quality of care, the short term costs of other common chronic 
conditions such as diabetes, hypertension, and Asthma/COPD will decrease among DLBCL 
patients as compared to those without cancer. 
1.4 Data Sources 
 We linked data from the following data sources for this study: 1) Surveillance 
Epidemiology and End-Results Program (SEER) cancer registries; 2) 5% Medicare sample for 
patients without any cancer; 3) Medicare claims of SEER and non-cancer patients; and 4) the 
Area Health Resource File (AHRF).  
1.4.1 Surveillance Epidemiology and End-Results Program (SEER) 
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 The SEER is an epidemiologic surveillance system representing about 28% of the US 
population residing in 20 population-based tumor registries (Alaska Native Tumor Registry, 
Arizona Indians, Cherokee Nation-Oklahoma, Connecticut, Detroit, Atlanta-Georgia, Greater 
Georgia, Rural Georgia, San Francisco-Oakland, San Jose-Monterey, Greater California, Hawaii, 
Iowa, Kentucky, Los Angeles, Louisiana, New Jersey, New Mexico, Seattle-Puget Sound, and 
Utah).44 The SEER cancer registries collect information for all the newly diagnosed cancer cases 
such as patient’s demographic characteristics, cancer site, date of cancer diagnosis, and cancer 
pathology (e.g., stage and grade). This information is included in the Patient Entitlement and 
Diagnosis Summary File (PEDSF).  
1.4.2 Medicare Sample of Non-Cancer Patients 
 We also utilized a 5% random sample of Medicare beneficiaries who did not have any 
cancer (except basal cell carcinoma) as the comparison group in this study. This sample of non-
cancer patients was derived from Medicare beneficiaries who resided in the SEER areas. The 
individuals in this sample who also appeared in the SEER data are removed. 
1.4.3 Medicare Claims 
 As majority of cancer cases are diagnosed among the elderly population aged 65 years 
and above, SEER patients’ Medicare claims can be utilized to obtain detailed information on 
medical treatment, chronic conditions, healthcare utilization, and expenditures. Medicare is the 
US government mandated insurance program for about 97% of the US population aged 65 years 
and above.45,46 The National Cancer institute (NCI) links SEER cases with Medicare enrolled 
patients using an individual’s last name, first name, social security number, and date of birth. 
More than 95% of the Medicare beneficiaries are enrolled in Medicare Part A and Part B 
coverage. Medicare Part A reimburses the use of inpatient care in hospitals and skilled nursing 
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facilities, home health care, and hospice care. Part B covers the use of physician and outpatient 
services. The Medicare beneficiaries enrolled in Health Maintenance Organizations (HMO) do 
not have all the information in their medical claims because these organizations are not mandated 
to submit all their service claims to the Center for Medicare and Medicaid (CMS). Hence, we 
excluded those Medicare beneficiaries who were enrolled in HMO at any time during the study 
period.  
 An encrypted identification number was provided for each Medicare beneficiary to link 
the PEDSF file from SEER with the Medicare files. The Medicare data consisted of Medicare 
Provider Analysis and Review (MEDPAR) files, the Carrier Claims (old name 
Physician/Supplier National Claims History (NCH)), Outpatient, Home Health Agencies (HHA), 
Hospice, Durable Medical Equipment (DME), and Part D Event (PDE). The MEDPAR file 
includes Medicare Part A claims records and the NCH and outpatient files consist of Part B 
claims for outpatient visits and physician services. Each claim record represents an episode of 
health service use and includes up to 12 diagnoses according to the International Classification of 
Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), service dates, and payments made 
by the CMS. The carrier claims file includes the physician specialty associated with the service 
provided. The carrier claims and outpatient claims files also include procedure codes according 
to the Healthcare Common Procedure Coding System (HCPCS). 
1.4.4 Area Health Resources File (AHRF) 
 The AHRF is a publicly available data file provided by the Department of Health and 
Human Services which contains information on more than 6,000 variables for each of the US 
counties.47 The AHRF contains data on the availability of health professionals, healthcare 
facilities, and socioeconomic and environmental characteristics of each county. We used the state 
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and county Federal Information Processing Standard (FIPS) codes to link the AHRF files with 
the SEER-Medicare dataset to measure the county level inter-personal, healthcare system, and 
community factors.  
1.5 Theoretical Framework 
We utilized the Social Ecological Model (SEM) as the theoretical framework for this 
study (Figure 1.1). We chose this model because patients’ visits to different provider specialties 
and use of mammography and BDT are influenced by both their personal characteristics as well 
as the surrounding social and organizational environments. Further, healthcare costs have been 
found to be a result of expenditure decisions made at micro (age, sex, health status) and macro 
(availability of hospitals, area poverty, area health insurance, travel time) levels.48 Hence, we 
utilized a multilevel SEM to examine the costs of chronic conditions among Medicare 
beneficiaries with DLBCL as compared to those without cancer. 
The SEM is an overarching framework to investigate the interactions between diverse 
personal and socio-physical factors that impact health behavior. The SEM provides a framework 
to integrate multiple individual and contextual theories of health behavior and presents a more 
comprehensive approach to study and modify particular behaviors.49 This theoretical perspective 
will help us in examining the key personal and environmental factors that are significant 
predictors of patients’ visits to a provider specialty and the receipt of preventive services.  
According to the SEM, the following multiple levels influence a health behavior: (1) 
intra-personal factors: personal characteristics such as socio-demographics, chronic conditions, 
stage of cancer, and cancer treatments; (2) inter-personal factors: formal and informal social 
support systems and networks made of family, friends, and colleagues (e.g., racial isolation index 
and social or cultural cohesion); (3) Healthcare system factors: characteristics of healthcare 
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system such as density of healthcare facilities and physicians; (4) community factors: 
relationships among organizations within a larger political or geographical area, which can be 
understood by SEER region, urban/rural region, area poverty and education, and; (5) public 
policy: local, state, or federal policies and laws that support or inhibit certain health practices 
such as policies and recommendations of IOM and USPSTF regarding the role of different 
provider specialties in cancer care and recommendations for preventive services.50-52  
There are five principles of SEM49: 1) Factors at multiple levels including intra-personal, 
inter-personal, healthcare system, community, and policy factors influence health behaviors. The 
relative effects of different factors vary with the particular behavior and context; 2) Contextual 
factors including physical and social environments of the individual are important determinants 
of health behavior; 3) Factors interact across multiple levels in modifying the health behavior. 
Various individual and contextual factors work together in promoting or inhibiting a health 
behavior; 4) Ecological models should be specific to the targeted behavior; and 5) Multilevel 
interventions implement changes at individual, organizational, environmental, and policy levels 
and hence, should be more effective than single level interventions. 
 14 
 
 
Figure 1.1 Social-Ecological Model of Health Behavior. 
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1.6 Innovation of the Study 
The visits to different provider specialties, receipt of preventive care, and the costs of 
care for DLBCL patients is largely unknown. Most previous studies examining the visits to 
different providers and preventive care have been conducted among patients with breast, 
colorectal, or prostate cancer during the follow-up period. There is a lack of research on the visits 
to PCPs, oncologists, and other medical specialists before cancer diagnosis, during cancer 
treatment, and at follow-up periods among patients with DLBCL. Specifically, our study will 
make the following novel contributions to literature:  
1. Lack of evidence among patients with DLBCL. Most existing studies have evaluated visits 
to different providers and receipt of mammography and BDT among patients with common 
malignancies such as breast, colorectal, and prostate cancers.53-57 Forsythe and colleagues 
conducted a survey among NHL patients after 2-5 years of cancer diagnosis.58 Many NHL 
patients were found to visit oncologists, PCPs, and other medical specialists (46.6%), while 
others saw only oncologists (12.9%), oncologists plus PCPs (24.6%), and oncologists plus other 
medical specialists (15.9%) for cancer follow-up care in last one year.58 However, the study was 
conducted in a small patient population (N = 363) in Los Angeles county. Further, the study by 
Forsythe et al. utilized self-reports of visits to providers which may be affected by recall bias. 
The study did not distinguish between the subtypes of NHL which have widely different 
prognosis and require different treatments.1 Our study examined the provider visits and receipt of 
preventive care by DLBCL patients, which is the most common subtype of NHL, by utilizing a 
national claims database of elderly Medicare beneficiaries with cancer. DLBCL is an aggressive 
form of cancer with unique treatments such as stem cell transplant. DLBCL can have a 
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significant effect on the preventive care and costs, which is different from the effect of other 
malignancies. 
2. Investigation of visits to specialists other than PCPs. Most past studies have focused on the 
roles of PCPs and oncologists only. A large proportion of cancer patients visit physicians of 
other medical specialties such as cardiologists, pulmonologists, and endocrinologists.59 Our 
study analyzed the visits to providers of all medical specialties at all the stages of cancer 
treatment and follow-up. 
3. Impact of cancer diagnosis on costs of chronic conditions. We could not find a study that 
examined the change in costs of common chronic conditions during cancer diagnosis, treatment, 
and follow-up periods. Our study examined the costs of chronic conditions and total costs of 
DLBCL patients before diagnosis, during treatment, and at follow-up period to fill this gap in 
literature. 
4. Visits to provider specialties during cancer treatment period. Most extant studies have 
examined the contact with physicians of different specialties and its effect on the outcomes of 
care after the cancer treatment period is over. There is limited evidence on the involvement of 
providers during the cancer treatment period. One study did not evaluate visits to physicians 
during cancer treatment period with an assumption that visits to PCPs will decrease.42 However, 
the IOM in its report on high quality cancer care, has emphasized the role of PCPs during the 
cancer treatment period. In order to better understand the role of different provider specialties 
during and after cancer treatment period, we examined the change in visits to physicians of 
different specialties before, during, and after the cancer treatment period.  
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5. Use of Social Ecological Model of health behavior. Visits to different provider specialties, 
preventive services, and costs of care are affected by both the individual and environmental 
factors. The factors at higher societal and community level such as the racial/ethnic composition, 
availability of providers, and community education level have a significant effect on access to 
care and healthcare utilization. A contextualized investigation of visits to and care received from 
different provider specialties has been lacking in existing studies. We utilized the Social 
Ecological Model of Health Behavior as the multilevel model to take into account the multiple 
levels of factors in a systematic way.60 
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Chapter 2: Impact of Diffuse Large B-Cell Lymphoma on Visits to Different Provider 
Specialties among Elderly Medicare Beneficiaries: Challenges for Care Coordination 
 
2.1 Abstract 
 Background. Newly diagnosed Diffuse Large B-Cell Lymphoma (DLBCL), a cancer with 
vague symptomatology, can pose significant challenges to care-coordination. Objective. We 
utilized a social-ecological model to understand the impact of DLBCL diagnosis on visits to 
primary care providers (PCPs) and specialists, a key component of care-coordination, over a 
three year period of cancer diagnosis and treatment. Methods. We used a retrospective 
longitudinal study design with SEER-Medicare linked dataset to analyze visits to PCPs and 
specialists by DLBCL patients (n=5,455) compared to non-cancer patients (n=14,770). Hurdle 
models and multivariable logistic regression were used to examine number of PCP visits and any 
visit to specialists, respectively. Results. DLBCL patients were more likely to visit PCPs (AOR 
[95%CI]: 1.25 [1.18, 1.31]), and had greater number of visits to PCPs (β, SE: 0.384, -0.014) than 
non-cancer patients. Further, DLBCL patients were more likely to have any visit to cardiologists 
(AOR [95%CI]: 1.40 [1.32, 1.47]), endocrinologists (1.43, [1.21, 1.70]), and pulmonologists 
(1.51 [1.36, 1.67]) than non-cancer patients. Among DLBCL patients, the number of PCP visits 
markedly increased during the treatment period compared to the baseline period (β, SE: 0.491, -
0.028) and then decreased to baseline levels (-0.464, -0.022). Conclusions. Visits to PCPs and 
specialists were much higher for DLBCL than non-cancer patients, which drastically increased 
during the DLBCL treatment period for chronic care. Treatment adverse effects and more 
frequent contact with healthcare system may have increased the visits to PCPs and specialists. 
Interventions to improve care-coordination may need to target the DLBCL treatment period, 
when care-coordination is most vulnerable. Implications. Practice: DLBCL patients have higher 
chronic care needs during the cancer treatment and follow-up periods and should be referred to 
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suitable mental health specialists when necessary. Policy: Policymakers who want to improve 
care-coordination for cancer patients may need to target the cancer treatment period. Research: 
Future studies need to investigate the cancer patients’ perceived barriers to care-coordination 
between their primary care providers, oncologists, and specialists.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 28 
 
2.2 Introduction 
Non-Hodgkin’s Lymphoma (NHL) is the most prevalent blood cancer with 
approximately 72,580 new cases of NHL expected to be diagnosed in 2016.1 Diffuse Large B-
cell Lymphoma (DLBCL) is the most common subtype of NHL and commonly occurs in adults 
above 64 years of age.2 DLBCL can lead to secondary cancers,3 post-traumatic stress,4 and poor 
quality of life in the elderly.5 Furthermore, 82.0% of elderly individuals have pre-existing 
chronic physical or mental health conditions.6,7 Therefore, individuals diagnosed with DLBCL 
receive care from multiple providers such as the oncologists, primary care physicians (PCPs), 
and other medical specialists (e.g., cardiologist, endocrinologists, psychologists, and others). 
Although not specific to DLBCL, elderly individuals visited an average of 6 different providers 
in a year.8 Previous studies have found that under the fee-for-service system, such receipt of 
uncoordinated care from multiple providers can lead to medication errors,9 duplication of 
services,10 emergency room visits,11 unplanned hospital readmissions,12 costs,10,13 and 
preventable hospitalizations13 and ultimately worsen the health outcomes of patients.14 In its 
report on cancer survivorship, Institute of Medicine recommended that individualized 
survivorship care plan should be developed to increase care coordination for cancer patients. The 
U.S. Department of Health and Human Services15 and the National Quality Forum16 have also 
developed strategic frameworks of care to identify novel models of care and include effective 
care coordination as one of the care quality measures.  
Care coordination may be further compromised with newly diagnosed cancer10 because 
cancer patients need care from multiple providers for their chronic conditions as well as cancer. 
For example, among breast cancer patients, visits to oncologists and PCPs increased after breast 
cancer diagnosis.17-19 Colorectal cancer patients had more visits to PCPs after the treatment 
period as compared to the pre-diagnosis period.20,21 These findings suggest that cancer patients 
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may be receiving care from both oncologists and PCPs. However, DLBCL patients may consult 
their PCPs or other medical specialists for symptoms, before being referred to an oncologist 
because they may experience vague symptoms such as painless swelling of lymph nodes, fever, 
and weight loss.22 The visits to PCPs and other medical specialists may continue during and after 
the cancer treatment period because, unlike other cancers, DLBCL can affect multiple organs.23 
In a cross-sectional survey conducted among NHL patients, 87.1% visited PCPs or other medical 
specialists, in addition to their oncologists.24 However, the investigators did not examine 
provider visits by patients with DLBCL which is markedly different in treatment and survival 
prognosis from other subtypes of NHL.2 DLBCL is an aggressive form of NHL and is often 
treated with intense therapeutic regimens such as stem cell transplant25,26 DLBCL treatment can 
worsen other chronic conditions or patients may have new diagnosis of chronic conditions due to 
increased contact with healthcare system. Therefore, the patterns of visits to PCPs and other 
medical specialists may differ. It is also plausible that due to the prioritization of cancer care, 
DLBCL patients may not continue to see their PCPs or other medical specialists after cancer 
diagnosis, specifically during the cancer treatment period.27 
To the best of our knowledge, no study has investigated whether DLBCL affects visits to 
PCPs and other medical specialists, an indicator of care coordination. It is important to examine 
DLBCL patients’ visits to PCPs and other medical specialists because cancer follow-up care in 
primary care settings is cost-effective.28 Further, oncologists are responsible for the treatment of 
cancer and may be less effective in providing care for other chronic conditions.29  
2.3 Theoretical Framework 
The primary objective of this study was to use the Social-Ecological model (SEM) to 
evaluate the impact of newly diagnosed DLBCL on visits to PCPs and other medical specialist 
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among the elderly Medicare beneficiaries compared to those without any cancer.30 The SEM is 
an overarching framework to investigate diverse personal and socio-physical factors that impact 
health behavior.30 We selected this framework because patients’ visits to providers can be 
influenced by patients’ personal characteristics as well as external social and healthcare 
environmental factors. These factors include: (a) intra-personal factors- patient’s socio-
demographic characteristics, chronic conditions, and cancer treatments received; (b) inter-
personal factors- county-level formal and informal social support systems c) healthcare system 
factors: density of physicians and facilities; (d) community factors- SEER region, urbanacity, 
area poverty and education.31-33 We used a nationally representative linked dataset of cancer 
registries and Medicare claims in the United States. The secondary objective of this study was to 
examine the change in PCP visits and use of medical specialists before and after DLBCL 
diagnosis. 
2.4 Methods 
2.4.1 Study Design 
We utilized a retrospective longitudinal design with 12-month pre-index and 24-month 
post-index periods. For the DLBCL patients, pre- and post-index periods were identified using 
the DLBCL diagnosis date as the index date. For the non-cancer patients, pre- and post-index 
periods were derived using randomly selected dates of service from inpatient or outpatient 
Medicare claims. The pre- and post-index period were divided into six equal time intervals of 6-
months each. For DLBCL patients, the pre-index period included baseline (t1) and pre-diagnosis 
(t2) and post-index period comprised of treatment (t3), post-treatment (t4), short follow-up (t5), 
and long follow-up (t6) periods.     
2.4.2 Data Sources 
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 We linked data from several sources: 1) SEER cancer registries; 2) 5% Medicare sample 
for patients without any cancer; 3) Medicare claims of SEER and non-cancer patients; and 4) the 
Area Health Resource File (AHRF). The SEER is an epidemiologic surveillance system 
consisting of data from 20 population-based tumor registries (Alaska Native Tumor Registry, 
Arizona Indians, Cherokee Nation-Oklahoma, Connecticut, Detroit, Atlanta-Georgia, Greater 
Georgia, Rural Georgia, San Francisco-Oakland, San Jose-Monterey, Greater California, Hawaii, 
Iowa, Kentucky, Los Angeles, Louisiana, New Jersey, New Mexico, Seattle-Puget Sound, and 
Utah).34 The SEER cancer registries collect information for all the newly diagnosed cancer cases 
such as patient’s demographic characteristics, cancer site, date of cancer diagnosis, and cancer 
pathology (e.g., stage and grade). Medicare claims can be linked to the SEER registries and 
contain detailed information on medical treatment, chronic conditions, healthcare utilization, and 
expenditures.   
 The AHRF is a publicly available data file provided by the Department of Health and 
Human Services which contains information on more than 6,000 variables for each of the US 
counties.35 The AHRF contains data on the availability of health professionals, healthcare 
facilities, and socioeconomic and environmental characteristics of each county. We used the state 
and county Federal Information Processing Standard (FIPS) codes to link the AHRF files with 
the SEER-Medicare dataset to measure the county level inter-personal, healthcare system, and 
community factors.  
2.4.3 Study Population 
The DLBCL was identified using the International Classification of Diseases for 
Oncology - Third Revision (ICD-O-3)/World Health Organization 2008 codes: 13, 14, 15, 16) 
during 2003-2011. The non-cancer patients were derived from a random 5% sample of Medicare 
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beneficiaries who resided in SEER areas between 2003 and 2011 and were not diagnosed with 
any cancer, except basal cell carcinoma. We selected a 10% random sample of non-cancer 
patients.   
The following exclusion criteria were applied to both DLBCL population and non-cancer 
sample: (a) with missing values for any demographic factor (e.g., age, sex, race, region, and End 
Stage Renal Disease (ESRD), (b) not alive during the observation period, (c) less than 66 years 
of age, (d) having ESRD, (e) enrolled in managed care plans, (f) not continuously enrolled in 
Medicare parts A and B during the pre- and post- index periods; and (g) not having any PCP visit 
during the entire observation period (Appendix 2.1 and 2.2). Additional inclusion criteria were 
applied to the DLBCL population: we included individuals if they had only one primary cancer 
(except basal cell carcinoma) and if their cancer was not diagnosed from autopsy or death 
certificate.  
2.4.4 Measures  
 Dependent variables. The dependent variables for our study included any visit to PCPs 
and other medical specialist. Further, we analyzed the number of PCP visits among those with at 
least one PCP visit. These variables were measured every 180 days (i.e. t1 through t6) and were 
derived from the National Claims History (NCH) files. The PCPs included general practice, 
family practice, internal medicine, geriatric medicine, nurse practitioner, or physician assistant.36 
Visits to other medical specialists were: (a) cardiologists among patients with any heart 
condition; (b) endocrinologists among patients with diabetes; (c) mental health specialists 
(psychologist or psychiatrist) among patients with depression and/or anxiety; and (d) 
pulmonologists among patients with asthma or chronic obstructive pulmonary disease (COPD). 
We identified the specialty of a physician by using the Health Care Financing Administration 
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(HCFA) specialty codes. The HCFA specialty codes from the SEER-Medicare dataset have been 
used in previous studies to examine the role of physician specialty in the care of breast and 
colorectal cancer patients.36-38  
 Cancer Status Independent Variable. The key independent variable was the presence 
of DLBCL vs. no cancer, which belonged to the domain of intra-personal factors as per SEM.  
 SEM Independent Variables. The independent variables in our study included both time 
varying and time invariant variables. The time varying factors included chronic conditions of 
arthritis, diabetes, any heart condition, any mental condition, and any respiratory condition and 
DLBCL treatments of chemotherapy, radiotherapy, and immunotherapy (only for those 
diagnosed with DLBCL). The time varying factors were measured repeatedly during each time 
interval from t1 to t6. All other intra-personal, inter-personal, healthcare, and community factors 
were time invariant and were measured during one year before the index date.  
 Intra-personal factors. (a) age at index date (66-69, 70-74, 75-79, or >=80 yrs.); (b) sex 
(male or female); (c) race (Non-Hispanic White, Non-Hispanic African American, Hispanic, or 
others); (d) geographic region (Northeast, South, North-Central, or West); (e) rural/urban (metro, 
urban, or rural); (f) arthritis (osteoarthritis or rheumatoid arthritis); (g) diabetes; (h) any heart 
condition (cardiac arrhythmia, coronary artery disease, or congestive heart failure); (i) depression 
or anxiety; (j) respiratory condition (Asthma or COPD); (k) DLBCL stage from the Ann Arbor 
staging system (stage I, II, III or IV); (l) chemotherapy; (m) radiotherapy; (n) immunotherapy; 
and (o) stem cell transplant. 
 Inter-personal factors. Inter-personal factors included county-level racial/ethnic 
isolation measured by: (a) percentage of Blacks; (b) percentage of Hispanics; and (c) social or 
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cultural cohesion measured by percentage of non-English speaking individuals above 18 years of 
age. 
 Healthcare system factors. Healthcare system factors were measured at the county 
level. These factors included: (a) health professional shortage area for PCPs (whole county, part 
of county, or no shortage); (b) quartiles of average number of hospitals per 10,000 elderly 
individuals above 65 years of age (0.56, 0.97, 1.31, 3.46); and (c) quartiles of average number of 
Federal Qualified Health Centers (FQHC) per 10,000 elderly individuals above 65 years of age 
(0.01, 0.37, 0.94, 3.68). 
 Community factors. Community factors included: (a) county percentage of individuals 
between 18 and 64 years of age without health insurance quartiles (13.10, 17.70, 22.57, 28.72); 
(b) county average travel time to work quartiles (19.73, 24.19, 27.44, 30.95); and (c) county 
percentage of individuals with below high school education quartiles (8.44, 12.27, 16.31, 25.01). 
In addition to the variables guided by SEM, we also included time and index year as covariates 
in all the models.  
2.4.5 Statistical Analyses  
We used chi-square tests to analyze the model-driven differences in intra-personal, inter-
personal, healthcare system, and community factors between DLBCL and the non-cancer 
patients. As repeated observations were made for PCP visits from t1 to t6, each subject was 
clustered over time. As each person had 6 observations, the observations were dependent and to 
account for the non-independence of observations, we used the unstructured correlation 
structure. We used hurdle models to analyze any visit to PCPs and the number of PCP visits. A 
hurdle model analyzes the two processes of generating zeroes and positive values separately.39 
The first part of the model, known as ‘hurdle at zero’, analyzes the occurrence of an outcome 
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(i.e., PCP visit or no visit). The second part of the model, known as ‘above the hurdle’, analyzes 
the positive values of the outcome (i.e., number of PCP visits above zero).40 Population-averaged 
logistic regression models (also known as Generalized Estimating Equations -GEE) were used to 
analyze the relationship between DLBCL and visit to providers.40 All analyses were conducted 
using STATA version 14.41 Our preliminary analysis indicated that there were significant 
differences in characteristics between the DLBCL and non-cancer patients. To reduce this 
observed selection bias between the DLBCL and non-cancer patients, we derived Inverse 
Probability Treatment Weights (IPTW) by conducting a logistic regression on DLBCL vs no 
cancer with the following independent variables: sex, race/ethnicity, age, index year, and chronic 
conditions. Results from the logistic regression are presented in Appendix 2.3. These IPTWs 
were used as weights in all the unadjusted and adjusted analyses.  
2.5 Results 
2.5.1 Description of DLBCL and Non-Cancer Patient Characteristics  
 Table 2.1 summarizes the selected characteristics of DLBCL and non-cancer patients 
before and after adjustments with IPTW. Before adjusting for observed selection bias with 
IPTW, DLBCL patients had higher percentage of males, whites, and above 75 years of age as 
compared to those with no cancer.  
2.5.2 Hurdle Model: Impact of DLBCL on Any Visit to PCP and Number of PCP Visits  
 A higher proportion of DLBCL patients visited PCPs as compared to non-cancer patients 
(t1: 75.3% vs 75.1%; t2: 84.1% vs 75.5%; t3: 92.3% vs 82.2%; t4: 81.4% vs 75.7%; t5: 80.5% vs 
77.3%; t6: 81.0% vs 77.9%). Figure 2.1 displays the differences in any visit to PCP between 
DLBCL patients and those without cancer from t1 to t6. Figure 2.2 summarizes the differences in 
the predicted number of PCP visits between the DLBCL and non-cancer patients. Without any 
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adjustments for chronic conditions, the number of visits to PCP were higher among those with 
DLBCL compared to the non-cancer patients (t1: 3.57 vs 3.46; t2: 4.29 vs 3.44; t3: 8.36 vs 3.55; 
t4: 5.12 vs 3.61; t5: 4.41 vs 3.63; t6: 4.50 vs 3.82). After adjusting for the presence of chronic 
conditions at each time period, DLBCL patients still had higher number of PCP visits (predicted) 
compared to non-cancer patients (t1: 5.00 vs 3.27; t2: 4.86 vs 3.42; t3: 5.28 vs 3.45; t4: 4.99 vs 
3.53; t5: 4.73 vs 3.53; t6: 4.48 vs 3.54). 
 Table 2.2 summarizes the parameter estimates from the unadjusted and adjusted hurdle 
models of any visit to PCP and the number PCP visits. After adjusting for all SEM independent 
variables, DLBCL patients were more likely to visit PCPs (AOR = 1.25, 95% CI = [1.18, 1.31]) 
and had more PCP visits (beta = 0.384, SE = -0.014) than non-cancer patients. 
2.5.3 SEM Independent Variables and Any Visit to PCP and Number of PCP Visits 
 Females, older individuals, other racial minorities (vs Whites), those living in South or 
North-Central compared to North-East, arthritis patients, heart disease patients, respiratory 
condition patients, mental health condition patients, and diabetes patients were more likely to 
visit PCPs and had higher number of PCP visits. Those living in counties with more hospitals 
and higher average travel time were less likely to have any PCP visit and had fewer PCP visits 
(Appendix 2.4). 
2.5.4 Impact of DLBCL on Any Visit to Other Medical Specialists  
 Figure 2.1 displays the differences in any visit to other medical specialists between 
DLBCL patients and those without cancer from t1 to t6. With regard to other medical specialties, 
a higher percentage of DLBCL patients visited cardiologists (t1: 70.2% vs 64.5%; t2: 62.8% vs 
54.9%; t3: 83.7% vs 51.9%; t4: 50.7% vs 46.4%; t5: 46.0% vs 45.3%; t6: 46.6% vs 44.6%), 
endocrinologists (t1: 7.6% vs 6.1%; t2: 7.0% vs 5.3%; t3: 8.8% vs 5.1%; t4: 6.6% vs 4.7%; t5: 
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6.0% vs 4.5%; t6: 6.1% vs. 4.8%), pulmonologists (t1: 25.8% vs 22.6%; t2: 23.7% vs 17.7%; t3: 
34.1% vs 15.2%; t4: 18.5% vs 13.3%; t5: 15.2% vs 12.8%; t6: 14.0% vs 12.1%), and 
rheumatologists (t1: 18.1% vs 11.0%; t2: 14.3% vs 7.9%; t3: 8.7% vs 7.5%; t4: 7.4% vs 6.3%; 
t5: 7.1% vs 6.1%; t6: 6.7% vs 5.6%) as compared to non-cancer patients. However, with regard 
to mental health specialists, we did not observe a clear pattern of use among DLBCL patients (t1: 
34.9% vs 31.1%; t2: 30.6% vs 33.9%; t3: 31.7% vs 30.6%; t4: 36.7% vs 33.9%; t5: 32.2% vs 
35.6%; t6: 37.1% vs 32.6%). DLBCL patients were more likely to visit cardiologists (AOR = 
1.40, 95%CI = [1.32, 1.47]), endocrinologists (1.43 [1.21, 1.70]), and pulmonologists (1.50 
[1.36, 1.67]) than patients with no cancer from both unadjusted and adjusted models (Table 2.3).  
2.5.5 SEM Independent Variables and Any Visit to Other Medical Specialties  
 Those with arthritis, asthma, mental health condition, or diabetes were more likely to 
have any visit to cardiologists. The elderly with any heart condition or mental health condition 
were more likely to have any visit to endocrinologists. The elderly with any heart condition, 
mental health condition, or diabetes were more likely to have any visit to pulmonologists. 
Further, females, other races, those living in North-Central or West region, and rural areas were 
less likely to have any visit to cardiologists and pulmonologists (Appendix 2.5).      
2.5.6 Change in Number of PCP visits over Time among DLBCL Patients  
 The results from the adjusted negative binomial regressions for number of PCP visits 
among beneficiaries with DLBCL are displayed in Table 2.4. When baseline period (t2) was 
used as the reference group, we observed that the number of PCP visits increased during pre-
diagnosis (t1) and treatment (t3) periods and decreased during the follow-up periods (t5, t6). 
When treatment period (t3) was used as the reference group, the number of visits during 
baseline, pre-diagnosis, post-treatment, and follow-up periods were significantly lower.   
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2.5.7 SEM Independent Variables and Number of PCP Visits among DLBCL Patients  
 Intra-personal factors associated with higher number of visits to PCPs among DLBCL 
patients included greater age, female sex, South, North-Central, or West region compared to 
North-East, arthritis, diabetes, any heart condition, depression or anxiety, and asthma or COPD 
(Appendix 2.6). With respect to DLBCL treatments, those receiving radiotherapy and 
immunotherapy had more PCP visits while those receiving stem cell transplants had less PCP 
visits. The inter-personal factors positively associated with lower number of PCP visits included 
living in counties with a higher percentage of Blacks. With respect to community factors, those 
living in counties with lower number of individuals with health insurance had lower PCP visits, 
and those living in counties with lower education level had higher PCP visits.  
2.6 Discussion 
In this first study of its kind, we examined the impact of newly diagnosed DLBCL on 
visits to different provider specialties to understand the challenges for care-coordination. We 
analyzed the impact of DLBCL on any PCP visit, number of PCP visits, and any visit to other 
medical specialists by using a robust study design that compared DLBCL patients with cancer-
free patients. Our study findings indicated that DLBCL patients were more likely to visit PCPs 
and had higher number of PCP visits as compared to those without any cancer, even after 
adjusting for intra-personal, inter-personal, healthcare system, and community factors. These 
findings are consistent with a previous study in breast cancer patients who had higher PCP visits 
than non-cancer patients.17  
Further, we found that DLBCL patients were more likely to visit other medical specialists 
as compared to non-cancer patients. This is a unique finding because none of the published 
studies examined the relationship between cancer diagnosis and visits to other medical 
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specialists, a key indicator of care coordination. This finding suggests problems for care 
coordination for patients enrolled in fee-for-service Medicare, because Medicare does not 
compensate the providers for communicating with other providers for care coordination. 
Providers have to face many challenges even with the availability of electronic health records 
due to a lack of interoperability between electronic health information systems.42  
With respect to change in PCP visits, our study findings are somewhat consistent with 
previous studies in colorectal and breast cancer patients, who were found to increase in their 
visits to PCP during the post-treatment period (i.e. one year after cancer diagnosis).17-20 Our 
study results indicated that the PCP visits increased three fold during the treatment period. One 
possible explanation for more visits to PCPs and other medical specialists among DLBCL 
patients is the presence of multiple chronic conditions. We observed that DLBCL patients had 
higher prevalence of diabetes, arthritis, any heart condition, depression or anxiety, and asthma or 
COPD than non-cancer patients. Our findings also indicated that many patients were newly 
diagnosed with chronic conditions after DLBCL diagnosis and treatment, which statistically 
explained the variations in number of PCP visits over time. These findings suggest that visits to 
PCPs and other medical specialists may be greater among DLBCL patients due to higher 
prevalence and incidence of chronic conditions, which can complicate the management of co-
occurring chronic conditions and cancer. Further, the chemotherapy and stem cell transplant are 
associated with significant adverse effects such as cardiotoxicity43 and loss of bone density.44 
These adverse effects may be another reason for the increase in visits to specialists during the 
treatment period. This sharp increase in provider visits poses significant challenges to care 
coordination. DLBCL patients may face greater difficulties in care coordination because the 
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roles of PCPs and other medical specialists have not been properly defined during the cancer 
treatment period.45,46  
Surprisingly, we did not find a significant difference in visits to mental health providers 
among elderly patients with both DLBCL and mental health conditions as compared to those 
without any cancer, after adjusting for time, index year, and other SEM factors. As the diagnosis 
and treatment of DLBCL leads to significant long term psychiatric morbidity such as anxiety, 
depression, post-traumatic stress disorder, and lower health status,47-49 it is concerning that 
DLBCL patients’ visits to mental health providers did not change. PCPs and oncologists may 
need to be more aware that the elderly DLBCL patients with pre-existing mental health 
conditions are highly susceptible to further mental health deterioration and should refer such 
patients to suitable mental health providers when necessary. 
Future studies need to investigate whether the strategic frameworks developed by the 
U.S. Department of Health and Human Services15 and the National Quality Forum16 can be 
implemented in the context of cancer care and can improve care-coordination for elderly patients 
with cancer and multiple chronic conditions. Another measure for improving the care-
coordination between oncologists and PCPs is the use of survivorship care plans. In response to 
the Institute of Medicine’s report on cancer survivorship, many groups have developed specific 
care plans for cancer patients.50 These care plans may be helpful in improving the coordination 
of care between providers during and after the treatment period.51  
Our study findings should be interpreted in the context of some limitations. We used the 
HCFA provider specialty codes given in the Physician/Supplier Claims file (NCH) of the SEER-
Medicare dataset to identify the provider specialties in this study. Although the HCFA codes 
have been used in previous studies on elderly cancer patients,36,52,53 these codes may not capture 
 41 
 
all the visits to different provider specialties.54 The purpose of our study was to examine the 
burden and opportunities for care coordination during the different phases of care among elderly 
patients with DLBCL. We did not investigate the actual provider-provider interaction or patients’ 
and providers’ experiences of care coordination in this study. Our study results can be 
generalized to Medicare fee-for-service beneficiaries who resided in SEER regions only.  
The strengths of our study include the use of SEER-Medicare database, which is a 
nationally representative data to examine the care of elderly patients with newly diagnosed 
cancer. We examined the visits to other medical specialists over a three year time period 
spanning the cancer diagnosis, treatment, and follow-up periods which had not been analyzed 
before. We used a comprehensive SEM framework to examine the association of various 
personal and contextual factors with the visits to different provider specialties among elderly 
DLBCL patients. Further, we utilized a robust study design with a non-cancer comparison group 
and time varying diagnosis of chronic conditions in our study.  
2.7 Conclusions 
The elderly Medicare beneficiaries with DLBCL were more likely to visit PCPs or other 
medical specialists and had higher number of visits to PCPs compared to non-cancer patients. 
The treatment adverse effects and more frequent contact with healthcare system may have led to 
increased diagnosis of other chronic conditions, which partially explained the higher visits to 
PCPs and specialists. The time period immediately after DLBCL diagnosis need to be targeted to 
implement interventions to improve care coordination between the oncologist, PCP, and other 
medical specialists.  
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Table 2.1 Description of Selected Characteristics of Elderly Medicare Beneficiaries with Diffuse Large 
B-Cell Lymphoma (DLBCL) and Non-Cancer Patients before and after Inverse Probability Treatment 
Weights. Surveillance Epidemiology and End Results Program (SEER) - Medicare 2003-2011. 
 
DLBCL Non-Cancer  DLBCL Non-Cancer 
 
N % N % Sig.   Col. wt % Col. wt % 
  All 5455 27.0 14,770 73.0  27.0 73.0 
Intra-Personal Factors 
Age (Years)     ***   
 
66-69      1,071  19.6      4,452  30.1  27.3 27.3 
 
70-74      1,374  25.2      3,914  26.5  26.4 26.2 
 
75-79      1,373  25.2      2,786  18.9  20.6 20.6 
 
>=80      1,637  30.0      3,618  24.5  25.7 25.9 
Sex     ***   
 
Female      3,029  55.5      9,479  64.2  62.2 61.9 
 
Male      2,426  44.5      5,291  35.8  37.8 38.1 
Race/Ethnicity     ***   
 
White      4,796  87.9    11,885  80.5  82.1 82.5 
 
African American        190  3.5      1,217  8.2  7.2 7.0 
 
Hispanic        120  2.2        379  2.6  2.5 2.5 
 
Others        349  6.4      1,289  8.7  8.1 8.1 
Geographic region     ***   
 
Northeast      1,113  20.4      2,885  19.5  20.0 19.8 
 
South      1,267  23.2      3,779  25.6  24.8 25.0 
 
North-central        720  13.2      1,752  11.9  12.1 12.2 
 
West      2,355  43.2      6,354  43.0  43.2 43.1 
Rural/Urban        
 
Metro      4,525  83.0    12,172  82.4  83.3 82.3 
 
Urban        815  14.9      2,278  15.4  14.7 15.5 
 
Rural        115  2.1        320  2.2  2.0 2.2 
Other Factor 
Index year      ***   
 2003        584  10.7      1,255  8.5  9.0 9.1 
 2004        589  10.8      1,349  9.1  9.8 9.6 
 2005        586  10.7      1,280  8.7  9.4 9.3 
 2006        584  10.7      1,432  9.7  10.3 10.0 
 2007        610  11.2      1,569  10.6  10.7 10.8 
 2008        609  11.2      1,653  11.2  11.3 11.2 
 2009        623  11.4      1,888  12.8  12.3 12.4 
 2010        624  11.4      2,052  13.9  13.1 13.2 
 2011        646  11.8      2,292  15.5  14.2 14.5 
Note. Based on 5,455 Medicare beneficiaries with Diffuse Large B-Cell Lymphoma and a random sample of 14,770 
beneficiaries without any cancer who resided in SEER areas. Weighted percentages were derived with using inverse 
probability treatment weights.  
Sig.: significance level; wt: Weighted  
*** p < .001 
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Table 2.2 Unadjusted and Adjusted Parameter Estimates of DLBCL vs No Cancer from Hurdle Models on Any Visit to PCP and 
Number of PCP Visits with Inverse Probability Treatment Weights. Surveillance Epidemiology and End Results Program (SEER)-
Medicare 2003-2011. 
 Any PCP Visit Number of PCP Visits 
 DLBCL Time DLBCL Time DLBCL*Time 
 OR 95% CI OR 95% CI β SE β SE β SE 
Model 1 1.388*** [1.317, 1.463] 1.034*** [1.026, 1.042] 0.428*** -0.015 0.016*** -0.002 -0.050*** -0.004 
Model 2 1.386*** [1.316, 1.461] 1.034*** [1.026, 1.042] 0.439*** -0.015 0.016*** -0.002 -0.052*** -0.004 
Model 3 1.243*** [1.179, 1.309] 0.950*** [0.941, 0.958] 0.382*** -0.014 -0.034*** -0.002 -0.050*** -0.004 
Model 4 1.245*** [1.182, 1.312] 0.948*** [0.940, 0.957] 0.384*** -0.014 -0.034*** -0.002 -0.049*** -0.004 
Note. Model 1: Unadjusted; Model 2: Adjusted for age, sex, race, region, rural/urban, index year; Model 3: Adjusted for 
age, sex, race, region, rural/urban, index year, arthritis, diabetes, heart conditions, depression/anxiety, asthma/chronic 
obstructive pulmonary disease; Model 4: Adjusted for age, sex, race, region, rural/urban, arthritis, diabetes, any heart 
condition, depression/anxiety, asthma/chronic obstructive pulmonary disease, county% black, county% hospitals, county% 
without health insurance, county average travel time, and county% below high school education. 
Based on 5,455 Medicare beneficiaries with Diffuse Large B-Cell Lymphoma and 19,215 beneficiaries without any cancer 
who resided in SEER areas. OR: Odds Ratios; CI: Confidence intervals; DLBCL: Diffuse Large B-Cell Lymphoma; SE: 
Standard errors. 
 *** p <.001  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 52 
 
Table 2.3 Unadjusted and Adjusted Estimates from Logistic Regression with Generalized Estimating 
Equation on Any Visit to Other Medical Specialists with Inverse Probability Treatment Weights. 
Surveillance Epidemiology and End Results Program (SEER)-Medicare 2003-2011. 
 Cardiologist Endocrinologist Pulmonologist 
 OR 95% CI OR 95% CI OR 95% CI 
Model 1       
DLBCL 1.409*** [1.336, 1.485] 1.485*** [1.250, 1.764] 1.578*** [1.423, 1.749] 
Time 0.940*** [0.932, 0.948] 1.024 [1.000, 1.050] 0.936*** [0.919, 0.953] 
 
Model 2 
      
DLBCL 1.396*** [1.324, 1.472] 1.431*** [1.206, 1.696] 1.505*** [1.358, 1.667] 
Time 0.923*** [0.914, 0.932] 1.008 [0.981, 1.035] 0.906*** [0.889, 0.925] 
Note. Model 1: Unadjusted; Model 2: Adjusted for age, sex, race, region, rural/urban, arthritis, diabetes, any heart 
condition, depression/anxiety, asthma/chronic obstructive pulmonary disease, county% black, county% hospitals, 
county average travel time, county% without health insurance, and county% below high school education. Any visit 
to other medical specialist was analyzed only among those with the corresponding chronic condition (e.g., any visit 
to endocrinologists was analyzed among those with diabetes).  
CI: Confidence intervals; OR: Odds ratios. 
*** p <.001  
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Table 2.4 Unadjusted and Adjusted Estimates from Negative Binomial Regressions with 
Generalized Estimating Equation on Number of Visits to Primary Care Physicians (PCPs) among 
elderly with Diffuse Large B-Cell Lymphoma (DLBCL). Surveillance Epidemiology and End 
Results Program (SEER)-Medicare 2003-2011. 
  Model 1 Model 2 Model 3 
  β SE β SE β SE 
Time       
 Baseline, t1 Ref.  Ref.  -0.491*** -0.0284 
 Pre-diagnosis, t2 0.201*** -0.017 0.134*** -0.016 -0.357*** -0.028 
 Treatment, t3 0.872*** -0.020 0.491*** -0.028 Ref.  
 Post-treatment, t4 0.337*** -0.020 0.027 -0.022 -0.464*** -0.022 
 Short follow-up, t5 0.188*** -0.020 -0.121*** -0.020 -0.612*** -0.026 
 Long follow-up, t6 0.220*** -0.020 -0.108*** -0.022 -0.599*** -0.027 
Note. Model 1: Unadjusted; Model 2&3:Adjusted for age, sex, race, region, rural/urban, marital status, arthritis, 
diabetes, any heart condition, depression/anxiety, asthma/chronic obstructive pulmonary disease, DLBCL stage, 
radiotherapy, chemotherapy, immunotherapy, stem cell transplant, county% black, county% hospitals, county% 
without health insurance, and county% below high school education.  
SE: Standard errors. 
**.05< p < .01, ***.01< p <.001 
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Figure 2.1 Differences in Any Visit to Primary Care Physician and Other Medical Specialists between Elderly 
Medicare Beneficiaries with Diffuse Large B-Cell Lymphoma and No Cancer. SEER Medicare 2003-2011. 
 
Note: Based on the differences in percentages of patients with any visit to provider between DLBCL and non-cancer 
patients for each time point.   
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Figure 2.2 Unadjusted and Adjusted Differences in Average Number of Visits to Primary Care Physicians between 
Elderly Medicare Beneficiaries with Diffuse Large B-Cell Lymphoma and No Cancer. SEER Medicare 2003-2011. 
 
Note. Calculated among those with at least one primary care physician visit. 
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Appendix 2.1 Flowchart of Sample Selection for Elderly Medicare Beneficiaries with Diffuse Large B-Cell 
Lymphoma.  
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Appendix 2.2 Flowchart of Sample Selection for Elderly Medicare Beneficiaries with No Cancer. 
.  
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Appendix 2.3 Adjusted Estimates from Logistic Regressions on 
Diffuse Large B-Cell Lymphoma vs. No Cancer by Selected 
Characteristics of Elderly Medicare Beneficiaries. Surveillance 
Epidemiology and End Results Program (SEER)-Medicare 2003-2011.   
  AOR 95% CI Sig. 
Sex    
 Female  0.66 [0.62, 0.70] *** 
 Male Ref.   
Age    
 70-74 1.40 [1.28, 1.54] *** 
 75-79 1.92 [1.74, 2.11] *** 
 >=80 1.81 [1.65, 1.99] *** 
 66-69 Ref.   
Race    
 African American 0.41 [0.35, 0.49] *** 
 Hispanic 0.73 [0.59, 0.91] ** 
 Others 0.66 [0.58, 0.75] *** 
 White Ref.   
Index Year    
 2003 Ref.   
 2004 0.94 [0.81, 1.08]  
 2005 0.96 [0.83, 1.10]  
 2006 0.85 [0.74, 0.98] * 
 2007 0.81 [0.71, 0.93] ** 
 2008 0.78 [0.68, 0.89] *** 
 2009 0.70 [0.61, 0.81] *** 
 2010 0.66 [0.58, 0.76] *** 
 2011 0.62 [0.54, 0.71] *** 
Region    
 South          0.95 [0.86, 1.04]  
 North-central 1.07 [0.95, 1.20]  
 West         1.03 [0.94, 1.12]  
 North East Ref.   
Baseline arthritis    
 Yes 1.20 [1.12, 1.29] *** 
 No Ref.   
Baseline any heart condition    
 Yes 1.23 [1.15, 1.32] *** 
 No Ref.   
Baseline diabetes    
 Yes 1.06 [0.99, 1.14]  
 No Ref.   
Baseline asthma or COPD    
 Yes 1.08 [1.00, 1.17]  
 No Ref.   
Note. Based on 5,455 Medicare beneficiaries with Diffuse Large B-Cell Lymphoma and 14,770 beneficiaries 
without any cancer who resided in SEER areas. AOR: Adjusted odds ratios; COPD: Chronic Obstructive Pulmonary 
Disease; Sig. significance. 
***p<.001 **.001<p<.01 *p<.05  
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Appendix 2.4 Adjusted Parameter Estimates from Hurdle Models on Any Visit to PCP and 
Number of PCP Visits with Inverse Probability Treatment Weights. Surveillance 
Epidemiology and End Results Program (SEER) Medicare 2003-2011. 
  Any Visit to PCP Number of PCP Visits 
  AOR 95% CI β SE 
DLBCL      
 Yes 1.245*** [1.182,1.312] 0.384*** -0.014 
 No Cancer Ref.  Ref.  
Time  
0.948*** [0.940,0.957] 
-0.034*** -0.002 
DLBCL*Time 
 
NA NA -0.049*** -0.004 
Sex     
 Female 1.382*** [1.322,1.446] 0.067*** -0.010 
 Male Ref.  Ref.  
Age (Years)     
 70-74 1.113*** [1.052,1.178] 0.039** -0.013 
 75-79 1.169*** [1.097,1.245] 0.065*** -0.015 
 >=80 1.308*** [1.230,1.390] 0.145*** -0.013 
 66-69 Ref.  Ref.  
Race     
 African American 0.893* [0.812,0.982] 0.012 -0.018 
 Hispanic 0.742*** [0.647,0.850] 0.038 -0.028 
 Others 1.243*** [1.134,1.363] 0.077*** -0.021 
 White Ref.  Ref.  
Region     
 South 1.553*** [1.422,1.697] 0.072*** -0.018 
 North-Central 1.071 [0.980,1.171] 0.111*** -0.018 
 West 1.058 [0.977,1.145] 0.069*** -0.017 
 North East Ref.  Ref.  
Rural/Urban      
 Rural 0.858*** [0.795,0.925] 0.016 -0.016 
 Urban 0.734*** [0.622,0.866] 0.012 -0.034 
 Metro Ref.  Ref.  
Arthritis     
 Yes 1.567*** [1.501,1.636] 0.190*** -0.009 
 No Ref.  Ref.  
Any heart condition     
 Yes 1.508*** [1.446,1.573] 0.333*** -0.010 
 No Ref.  Ref.  
Asthma or COPD     
 Yes 1.464*** [1.391,1.540] 0.227*** -0.011 
 No Ref.  Ref.  
Depression/anxiety     
 Yes 2.233*** [2.076,2.403] 0.333*** -0.013 
 No Ref.  Ref.  
Diabetes     
 Yes 1.824*** [1.741,1.911] 0.202*** -0.010 
 No Ref.  Ref.  
County% Blacks     
 1.26 Ref.  Ref.  
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Appendix 2.4 Adjusted Parameter Estimates from Hurdle Models on Any Visit to PCP and 
Number of PCP Visits with Inverse Probability Treatment Weights. Surveillance 
Epidemiology and End Results Program (SEER) Medicare 2003-2011. 
 4.51 0.922* [0.861,0.988] -0.026 -0.015 
 9.85 0.960 [0.886,1.041] 0.006 -0.017 
 30.52 0.970 [0.887,1.061] -0.044* -0.018 
County% Hospitals     
 0.56 Ref.  Ref.  
 0.97 1.035 [0.967,1.107] 0.012 -0.016 
 1.31 1.005 [0.938,1.076] -0.009 -0.015 
 3.46 0.900* [0.829,0.976] -0.039* -0.017 
County% without health insurance     
 13.10 Ref.  Ref.  
 17.70 0.920* [0.853,0.992] 0.001 -0.015 
 22.57 0.751*** [0.687,0.822] -0.020 -0.018 
 28.72 0.782*** [0.706,0.865] -0.031 -0.020 
County average travel time     
 19.73 Ref.  Ref.  
 24.19 0.968 [0.905,1.035] -0.038** -0.014 
 27.44 0.902** [0.839,0.970] -0.018 -0.015 
 30.95 0.827*** [0.764,0.894] -0.061*** -0.016 
County% less than high school 
education 
    
 8.44 Ref.  Ref.  
 12.27 0.978 [0.912,1.049] 0.005 -0.014 
 16.31 1.03 [0.952,1.116] 0.042** -0.016 
 25.01 1.032 [0.943,1.130] 0.081*** -0.018 
Note. Based on 5,455 Medicare beneficiaries with Diffuse Large B-Cell Lymphoma (DLBCL) and 14,770 
beneficiaries without any cancer who resided in SEER areas. Adjusted beta coefficients and standard errors are from 
Generalized Estimating Equation with negative binomial distribution and unstructured correlation matrix. AOR: 
Adjusted odds ratios; CI: Confidence interval; COPD: Chronic Obstructive Pulmonary Disease; PCP: Primary Care 
Physician; Sig. significance. 
***p<.001 **.001<p<.01 *p<.05 
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Appendix 2.5 Adjusted Parameter Estimates from Logistic Regression with Generalized Estimating Equations on 
Any Visit to Other Medical Specialists with Inverse Probability Treatment Weights. Surveillance Epidemiology and 
End Results Program (SEER) Medicare 2003-2011. 
  Cardiologists Endocrinologists Pulmonologists 
  AOR 95% CI AOR 95% CI AOR 95% CI 
DLBCL        
 Yes 1.396*** [1.324, 1.472] 1.431*** [1.206, 1.696] 1.505*** [1.358, 1.667] 
 No Cancer Ref.  Ref.  Ref.  
Time  
0.923*** [0.914, 0.932] 1.008 [0.981, 1.035] 0.906*** [0.889, 0.925] 
Sex       
 Female  0.748*** [0.707, 0.791] 1.104 [0.928, 1.314] 0.888* [0.798, 0.988] 
 Male Ref.  Ref.  Ref.  
Age (Years)       
 70-74 1.086* [1.007, 1.170] 1.028 [0.827, 1.276] 1.012 [0.874, 1.172] 
 75-79 1.162*** [1.074, 1.258] 0.825 [0.650, 1.047] 1.136 [0.974, 1.325] 
 >=80 1.190*** [1.105, 1.282] 0.638*** [0.500, 0.815] 0.869 [0.748, 1.010] 
 66-69 Ref.  Ref.  Ref.  
Race       
 African 
American 0.765*** [0.686, 0.852] 0.9 [0.644, 1.258] 0.965 [0.769, 1.211] 
 Hispanic 0.880 [0.743, 1.042] 0.582 [0.317, 1.067] 0.822 [0.589, 1.147] 
 Others 0.818*** [0.737, 0.907] 0.808 [0.599, 1.091] 0.815 [0.654, 1.016] 
 White Ref.  Ref.  Ref.  
Region       
 South          1.062 [0.954, 1.181] 0.599** [0.439, 0.819] 0.955 [0.778, 1.172] 
 North-Central 0.827*** [0.744, 0.919] 0.489*** [0.356, 0.672] 0.835 [0.682, 1.023] 
 West         0.777*** [0.706, 0.855] 0.619*** [0.478, 0.802] 0.825* [0.686, 0.992] 
 North East Ref.  Ref.  Ref.  
Rural/Urban       
 Rural 0.803*** [0.728, 0.887] 0.724 [0.496, 1.056] 0.766* [0.624, 0.941] 
 Urban 0.747** [0.611, 0.912] 0.640 [0.286, 1.430] 0.777 [0.522, 1.155] 
 Metro Ref.  Ref.  Ref.  
Arthritis       
 Yes 1.089*** [1.039, 1.141] 1.019 [0.887, 1.170] 1.036 [0.941, 1.139] 
 No Ref.  Ref.  Ref.  
Any heart condition       
 Yes NA  1.310*** [1.141, 1.504] 1.620*** [1.451, 1.807] 
 No   Ref.  Ref.  
Asthma or COPD        
 Yes 1.184*** [1.128, 1.243] 0.975 [0.839, 1.133] NA  
 No Ref.  Ref.    
Depression/anxiety        
 Yes 1.390*** [1.313, 1.472] 1.226** [1.077, 1.396] 1.312*** [1.193, 1.444] 
 No Ref.  Ref.  Ref.  
Diabetes       
 Yes 1.172*** [1.118, 1.229] NA  1.109* [1.009, 1.218] 
 No Ref.    Ref.  
County% Blacks       
 1.26 Ref.  Ref.  Ref.  
 4.51 0.957 [0.876, 1.045] 1.161 [0.872, 1.546] 1.164 [0.973, 1.394] 
 62 
 
Appendix 2.5 Adjusted Parameter Estimates from Logistic Regression with Generalized Estimating Equations on 
Any Visit to Other Medical Specialists with Inverse Probability Treatment Weights. Surveillance Epidemiology and 
End Results Program (SEER) Medicare 2003-2011. 
 9.85 0.965 [0.875, 1.065] 1.212 [0.881, 1.668] 1.253* [1.032, 1.522] 
 30.52 0.978 [0.877, 1.089] 1.345 [0.947, 1.910] 1.172 [0.954, 1.440] 
County% Hospitals       
 0.56 Ref.  Ref.  Ref.  
 0.97 0.953 [0.877, 1.035] 0.916 [0.725, 1.156] 0.955 [0.814, 1.122] 
 1.31 0.942 [0.866, 1.026] 0.762* [0.592, 0.982] 0.984 [0.832, 1.164] 
 3.46 0.940 [0.847, 1.042] 0.772 [0.530, 1.124] 0.881 [0.712, 1.091] 
County% without health 
insurance 
      
 13.10 Ref.  Ref.  Ref.  
 17.70 0.968 [0.883, 1.061] 1.117 [0.859, 1.451] 1.021 [0.859, 1.214] 
 22.57 1.000 [0.896, 1.115] 1.541* [1.106, 2.148] 0.955 [0.776, 1.176] 
 28.72 0.945 [0.834, 1.070] 1.356 [0.935, 1.966] 0.946 [0.747, 1.199] 
County average travel time       
 19.73 Ref.  Ref.  Ref.  
 24.19 1.042 [0.957, 1.134] 1.165 [0.867, 1.566] 0.920 [0.776, 1.089] 
 27.44 1.054 [0.964, 1.152] 1.391* [1.031, 1.877] 1.006 [0.844, 1.198] 
 30.95 1.129* [1.025, 1.244] 1.595** [1.181, 2.155] 1.051 [0.870, 1.271] 
County% less than high 
school education 
      
 8.44 Ref.  Ref.  Ref.  
 12.27 0.987 [0.904, 1.077] 0.804 [0.618, 1.047] 0.928 [0.782, 1.101] 
 16.31 0.987 [0.894, 1.089] 0.771 [0.554, 1.074] 0.879 [0.728, 1.060] 
 25.01 0.992 [0.887, 1.111] 0.622** [0.437, 0.885] 0.857 [0.689, 1.065] 
Note. Any visit to other medical specialist was analyzed only among those with the corresponding chronic condition 
(e.g., any visit to endocrinologists was analyzed among those with diabetes).  
CI: Confidence intervals; COPD: Chronic Obstructive Pulmonary Disease; OR: Odds ratios. 
 ***p<.001 **.001<p<.01 *p<.05 
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Appendix 2.6 Adjusted Estimates from Negative Binomial 
Regression with Generalized Estimating Equation on Number of 
PCP Visits with Inverse Probability Treatment Weights among 
Elderly with Diffuse Large B-Cell Lymphoma. Surveillance 
Epidemiology and End Results Program (SEER) Medicare 
2003-2011.   
  Number of PCP Visits 
  β SE 
Time    
 Baseline, t1 Ref.  
 Pre-diagnosis,t2 0.133*** 0.016 
 Treatment,t3 0.491*** 0.028 
 Post-treatment,t4 0.027 0.022 
 Short followup,t5 -0.121*** 0.02 
 Long followup,t6 -0.108*** 0.022 
Age groups   
 66-69 Ref.  
 70-74 0.041 0.024 
 74-79 0.046 0.025 
 >=80 0.082*** 0.025 
Sex    
 Female 0.059*** 0.017 
 Male Ref.  
Race    
 Whites Ref.  
 African American -0.065 0.04 
 Hispanics 0.070 0.055 
 Others 0.065 0.033 
Marital status   
 Single Ref.  
 Married -0.049 0.037 
 Separated/Divorced/ 
Widowed -0.036 0.039 
Region    
 Northeast Ref.  
 South 0.089** 0.032 
 North-Central 0.139*** 0.033 
 West 0.100*** 0.027 
Rural/Urban   
 Metro Ref.  
 Urban 0.044 0.027 
 Rural 0.005 0.056 
DLBCL stage   
 Stage I Ref.  
 Stage II -0.020 0.023 
 Stage III -0.007 0.025 
 Stage IV 0.030 0.021 
Radiotherapy   
 Yes 0.085*** 0.023 
 No Ref.  
Chemotherapy   
 Yes -0.025 0.024 
 No Ref.  
Immunotherapy   
 Yes 0.099*** 0.028 
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Appendix 2.6 Adjusted Estimates from Negative Binomial 
Regression with Generalized Estimating Equation on Number of 
PCP Visits with Inverse Probability Treatment Weights among 
Elderly with Diffuse Large B-Cell Lymphoma. Surveillance 
Epidemiology and End Results Program (SEER) Medicare 
2003-2011.   
  Number of PCP Visits 
  β SE 
 No Ref.  
Stem cell transplant   
 Yes -0.060*** 0.017 
 No Ref.  
Arthritis    
 Yes 0.171*** 0.016 
 No Ref.  
Diabetes    
 Yes 0.209*** 0.016 
 No Ref.  
Any heart condition   
 Yes 0.295*** 0.016 
 No Ref.  
Depression/Anxiety   
 Yes 0.324*** 0.021 
 No Ref.  
Asthma/COPD   
 Yes 0.170*** 0.017 
 No Ref.  
County% blacks   
 1.14 Ref.  
 4.21 -0.059* 0.025 
 9.46 -0.007 0.03 
 28.38 -0.093** 0.032 
County% hospitals   
 0.56 Ref.  
 0.96 0.024 0.025 
 1.30 -0.001 0.024 
 3.48 -0.038 0.028 
County% without health insurance   
 12.89 Ref.  
 17.21 0.015 0.025 
 22.07 -0.048 0.03 
 28.24 -0.074* 0.033 
County average travel time  
 19.50 Ref.  
 24.09 -0.037 0.023 
 27.42 -0.010 0.025 
 31.06 -0.050 0.027 
County% less than high school 
education 
  
 8.27   
 11.99 0.039 0.024 
 15.75 0.082** 0.028 
 24.52 0.118*** 0.031 
Note. Based on 5,455 Medicare beneficiaries with Diffuse Large B-Cell Lymphoma (DLBCL) who had at least one 
PCP visit during t1 to t6. Adjusted beta coefficients and standard errors are from Generalized Estimating Equation 
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with negative binomial distribution and unstructured correlation matrix. COPD: Chronic Obstructive Pulmonary 
Disease; PCP: Primary Care Physician. 
***p<.001 **.001<p<.01 *p<.05
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Chapter 3: Receipt of Mammography and Bone Density Testing by Women with Diffuse 
Large B-Cell Lymphoma. 
3.1 Abstract 
 Background. Women with Diffuse Large B-Cell Lymphoma (DLBCL) are at a higher 
risk of breast cancer and osteoporosis than the general population. The receipt of mammography 
and bone mineral density testing (BDT) by women with DLBCL is unknown. Objective. We 
utilized a social-ecological model (SEM) with Surveillance, Epidemiology, and End Results 
(SEER)-Medicare linked dataset to analyze the receipt of mammography among female DLBCL 
patients (n=1,137) aged 66-74 years and BDT among those aged >66 years (n=3,029) compared 
to female non-cancer patients (n=6,376 & 13,366, respectively). Methods. We used multivariable 
logistic regressions with Inverse Probability Treatment Weights to control for observed selection 
bias. Results. There was no significant difference in mammography between women with 
DLBCL (59.8%) and no cancer (60.2%); both of which were well below the Healthy People 
2020 target (81.1%; both p < .0001). Female DLBCL patients had slightly lower rate of BDT 
(18.5%) than non-cancer patients (19.6%; p > .05). After adjusting for PCP visits, DLBCL 
patients were less likely to have mammography (AOR [95%CI]: 0.82 [0.71, 0.94]) and BDT 
(0.80 [0.71, 0.90]) than non-cancer patients. Further, those with more primary care physician 
visits were more likely to have mammography (1.62 [1.48, 1.77]) and BDT (1.60 [1.50, 1.71]). 
Radiotherapy and stem cell transplant were not associated with mammography and BDT, 
respectively (both p >.05). Conclusions. Prioritization of cancer and chronic care may be causing 
sub-optimal mammography and BDT among female DLBCL patients. Providers should increase 
the recommendations for mammography in those receiving radiotherapy and BDT in stem cell 
transplant patients, to reduce the morbidity and mortality from breast cancer and fractures in 
women with DLBCL.  
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3.2 Introduction 
Non-Hodgkin’s Lymphoma (NHL) is the most common hematologic cancer in the United 
States, with about 72,580 new cases diagnosed in 2016.1 Diffuse Large B-Cell Lymphoma 
(DLBCL) is the most common subtype of NHL and commonly occurs in adults above 64 years 
of age.2 Advances in the treatment of DLBCL such as immunotherapy with Rituximab3 and 
hematopoietic stem cell transplantation4 have led to a marked improvement in the five-year 
survival rate to approximately 60.5%.5 However, DLBCL patients are at a higher risk of 
secondary cancers and adverse treatment effects than general population.6,7 Of particular concern 
are the risks of breast cancer and loss of bone mineral density among women with DLBCL.4,6   
3.2.1 Risk of Breast Cancer 
Breast cancer is the most common cancer among women, with 246,660 new cases 
expected to be diagnosed in 2016.8 Older female DLBCL patients who received radiotherapy are 
at a threefold risk of breast cancer than general population.6,9,10 Female breast cancer patients 
with a history of lymphoma had significantly lower five-year disease free survival (54%) and 
overall survival (87%) as compared to breast cancer patients with no history of lymphoma (91% 
and 98%, respectively).11 Breast cancer screening with mammography can lead to early 
treatment due to good sensitivity (68%) and high specificity (93%) for detecting breast cancer in 
lymphoma patients.12-14  
Increasing the rate of mammography screenings is essential to meet the Healthy People 
2020 target of 81.1% for women aged 50-74 years.15 Since 2009, the US Preventive Services 
Task Force (USPSTF) recommends biennial mammography screening for women between 50-74 
years of age.16 Consistent with the USPSTF guidelines, the American Cancer Society also 
 68 
 
recommends mammograms every 2 years for women aged 55 and older.17 It is critical to 
examine the receipt of mammography among DLBCL patients as mammography use can be 
negatively affected by the competing demands of acute DLBCL treatment, which the provider 
may deem more necessary for patient’s survival.18-20  
3.2.2 Risk of Bone Density Loss 
 Another well-known adverse consequence of DLBCL treatment is the loss of bone 
density in women, which can lead to negative sequelae such as osteoporosis and fractures.4,21 
Bone density loss is high in elderly post-menopausal women,22 which can be aggravated by 
chemotherapy, corticosteroids, and hematopoietic cell transplantation in women with DLBCL.23-
25 For example, female lymphoma patients who received stem cell transplant had eightfold odds 
of reporting osteoporosis than siblings without cancer.24 NHL patients with chemotherapy had 
higher rates of fractures (31%) and osteoporosis (10%) as compared to NHL patients who did not 
receive chemotherapy (19% and 8%, respectively). The USPSTF recommends bone mineral 
density testing (BDT) for osteoporosis in women aged ≥65 years without previous known 
fractures or secondary causes of osteoporosis.26 BDT by dual photon densitometry at one year is 
recommended among stem cell transplant recipients due to their elevated risk of having bone 
density loss.27  
 Older Medicare beneficiaries have been found to have low rates of BDT in a previous 
study.28 Some reasons for underuse of BDT include the uncertainty of site and frequency of 
testing, lack of a cut-off value for fracture risk, and limited predictive value of BDT for 
fractures.29 Further, there are several other risk factors for fractures which are independent of 
bone mineral density such as history of fracture, maternal history of fracture, age, and low serum 
levels of estradiol.29 However, BDT is currently the most effective measure for predicting the 
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risk of fractures in post-menopausal women30-3233 and should be provided to female DLBCL 
patients. Increasing the rates of BDT is crucial to achieve the Healthy People 2020 target of 
reducing osteoporosis cases and hospitalizations due to fractures.34 
3.2.3 Predictors of Screenings 
Cancer patients have been found to be more likely to have preventive screenings than 
non-cancer patients. For example, breast cancer patients were more likely to receive 
mammography (74.0%) and BDT (8.3%) than matched non-cancer controls (41.0% and 6.8%, 
respectively).35 Similarly, colorectal cancer patients were more likely to receive a mammogram 
(49.8%) than matched non-cancer patients (47.4%).36 Primary Care Physicians (PCPs) play an 
important role in providing preventive screenings to women with cancer,35,37,38 and 
recommendation by PCP is the one of the best predictors of cancer screening adherence.39,40 
Breast cancer patients with more visits to PCP were twice as likely to receive mammography37 
and colorectal patients with more PCP visits were twice as likely to receive BDT.41 We could not 
identify any study examining the use of mammography and BDT among women with DLBCL; 
research investigating mammography and BDT in this population is needed, as DLBCL is a 
more aggressive cancer and is treated with an intense therapeutic regimen, which may increase 
the risk for second primary cancers.42 DLBCL treatment increases the risk of breast cancer and 
loss of bone density in women, and it is necessary to analyze the factors that can affect 
mammography screening and BDT in these patients to improve their quality and quantity of life.   
3.3 Theoretical Framework  
 We utilized the Social Ecological Model (SEM) to examine the factors that can affect the 
receipt of mammography and BDT. The SEM is an overarching theoretical framework to 
examine the association of diverse personal and surrounding socio-physical factors with a health 
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behavior.43,44 These factors consist of: 1) intra-personal factors - patient’s demographic 
characteristics, other chronic conditions, and treatments received for DLBCL; 2) inter-personal 
factors – patients’ social network of friends, family, or colleagues; (c) healthcare system factors 
– availability of hospitals and physicians; and (d) community factors - characteristics of the 
surrounding geographical area including SEER region, urban/rural region, area poverty, and area 
education.44-46 Previous studies have used the SEM to examine the geographic variations in 
mammography and colorectal screenings.45,47,48 We utilized this framework to examine the 
association of multiple individual and contextual factors with the receipt of mammography and 
BDT in women with DLBCL as compared to women without any cancer.  
3.4 Methods 
3.4.1 Study Design 
 We used a retrospective cohort study design with 12 month baseline and 24 month 
follow-up periods. We identified the baseline and follow-up periods using the DLBCL diagnosis 
date as the index date for DLBCL patients. For the non-cancer patients, we derived the baseline 
and follow-up periods by using a random service date from inpatient or outpatient Medicare 
claims. 
3.4.2 Data Sources 
 We utilized the following data sources for this study: 1) Surveillance, Epidemiology and 
End Results Program (SEER) cancer registry data; 2) 5% sample of Medicare patients without 
any cancer; 3) Medicare claims of patients from SEER and non-cancer patients; and 4) the Area 
Health Resource File (AHRF). SEER is an epidemiologic cancer surveillance system including 
data from 20 cancer registries (Alaska Native Tumor Registry, Arizona Indians, Cherokee 
Nation-Oklahoma, Connecticut, Detroit, Atlanta-Georgia, Greater Georgia, Rural Georgia, San 
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Francisco-Oakland, San Jose-Monterey, Greater California, Hawaii, Iowa, Kentucky, Los 
Angeles, Louisiana, New Jersey, New Mexico, Seattle-Puget Sound, and Utah).49 These cancer 
registries collect information for patients with newly diagnosed cancers such as patient’s 
demographic characteristics, site of cancer diagnosis, date of cancer diagnosis, and cancer stage 
or grade (e.g., DLBCL stage). Medicare claims of beneficiaries who resided in SEER areas can 
be linked to the SEER registries to collect detailed information on medical treatment, chronic 
conditions, healthcare utilization, and costs.   
 The AHRF is a publicly available data provided by the Department of Health and Human 
Services.50 We used the AHRF file to obtain information on the availability of health 
professionals, healthcare facilities, and socioeconomic and environmental characteristics of each 
county. We used the state and county Federal Information Processing Standard (FIPS) codes to 
link the SEER-Medicare dataset with AHRF files.  
3.4.3 Study Sample   
 For the outcome of BDT, we included 3,029 female Medicare beneficiaries with age >66 
years with a primary diagnosis of DLBCL (International Classification of Diseases for Oncology 
- Third Revision (ICD-O-3)/World Health Organization 2008 codes: 13, 14, 15, 16) during 2003-
2011 (Appendix 3.1). For mammography screening, we included 1,137 female beneficiaries with 
a primary diagnosis of DLBCL who were between 66-74 years of age (Appendix 3.1). We only 
included patients who had one primary DLBCL cancer diagnosis (except basal cell carcinoma) 
and who were not diagnosed with cancer from autopsy. 
 We selected the non-cancer patients from a random 5% sample of Medicare beneficiaries 
who resided in SEER areas during 2003-2011 and were not diagnosed with any cancer, except 
basal cell carcinoma. From this non-cancer dataset, we selected a 10% random sample of female 
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Medicare beneficiaries as the comparison group. We included 11,956 female Medicare 
beneficiaries > 66 years of age for BDT and 5,686 female beneficiaries between 66-74 years of 
age for mammography screening as the non-cancer comparison group (Appendix 3.2). 
 We applied the following exclusion criteria to both DLBCL and non-cancer patients: 1) 
less than 66 years of age; 2) having End Stage Renal Disease (ESRD); 3) not alive during the 
baseline or follow-up periods; 4) enrolled in managed care plans; 5) not continuously enrolled in 
Medicare parts A and B during the baseline and follow-up periods; 6) not having any PCP visit 
during the baseline and follow-up periods; and 7) missing values for age, sex, race, region, or 
ESRD. 
3.4.4 Measures  
 Dependent variables. We analyzed two dependent variables in this study: the receipt of 
mammography screening and the receipt of BDT. Before 2009, mammography screening was 
recommended every 1-2 years for women aged 40 and older.51 In 2009, the USPSTF revised the 
recommended screening mammography interval to every two years. To examine if the rates of 
mammography are consistent with the current USPSTF and American Cancer Society guidelines, 
we used the time interval of two years for mammography screening in our study. For 
osteoporosis screening, although the USPSTF has not recommended an optimal interval for 
repeated screening, a minimum of two years period has been suggested to reliably detect a 
change in bone mineral density.31,52 Hence, we measured the receipt of osteoporosis screening 
during the two year follow-up period. Further, we adjusted for the year of index date as one of 
the independent variable. We used the diagnosis and procedure codes in inpatient and outpatient 
Medicare claims files to measure these variables. We excluded diagnostic mammography 
screening from the analysis and only included the codes for screening mammography. We 
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included BDT with dual energy X-Ray absorptiometry, photon absorptiometry, or Computed 
Tomography scan in this study.29   
Key Independent Variable – Cancer Status. The key independent variable for this study was 
the presence of DLBCL compared with no cancer. The diagnosis of DLBCL belonged to the 
domain of intra-personal factors from the SEM.  
SEM Independent Variables 
 The intra-personal factors of radiotherapy, chemo-immunotherapy and stem cell 
transplant for DLBCL patients were measured during one year after the DLBCL diagnosis. All 
other intra-personal, inter-personal, healthcare system, and community factors were measured 
during the one year baseline period before the index date.   
 Intra-personal factors. 1) Average monthly PCP visits before first mammography or 
first BDT: PCP specialties included general practice, family practice, internal medicine, geriatric 
medicine, nurse practitioner, physician assistant, or obstetrics-gynecology.35 Obstetrics-
Gynecologists serve as PCPs for many women53-55 and have been included as a PCP specialty in 
previous studies.56 Among those who did not receive mammography or BDT, we calculated the 
average monthly visits to PCP during the follow-up period of 24 months. We identified PCP 
specialty by using the Health Care Financing Administration (HCFA) specialty codes35,57,58 ; 2) 
age at index date (66-69 or 70-74 yrs.); 3) race (Non-Hispanic White, Non-Hispanic African 
American, Hispanic, or others); 4) rurality: We used urban/rural recode to classify region into 
metro (counties with <250,000 to one million population), urban (counties with 2,500 to >20,000 
population), and rural (counties with less than 2,500 population)49; 5) geographic region 
(Northeast, South, North-Central, or West); 6) arthritis (osteoarthritis or rheumatoid arthritis); 7) 
any heart condition (cardiac arrhythmia, congestive heart failure, or coronary artery disease); 8) 
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diabetes; 9) depression or anxiety; and 10) Asthma or Chronic Obstructive Pulmonary Disease 
(COPD). The intra-personal factors specific to DLBCL patients included: 1) Ann Arbor stage of 
DLBCL (stage I, II, III or IV); 2) radiotherapy; 3) chemo-immunotherapy; and 4) stem cell 
transplant. 
 Inter-personal factors. Inter-personal factors included county-level 1) percentage of 
Blacks; 2) percentage of Hispanics; and 3) percentage of non-English speaking individuals above 
18 years of age. 
 Healthcare system factors. Healthcare system factors included county level: 1) average 
number of hospitals per 10,000 individuals above 65 years of age; 2) PCP shortage area (whole 
county, part of county, or no shortage); and 3) average number of Federal Qualified Health 
Centers (FQHC) per 10,000 individuals above 65 years of age. 
 Community factors. Community factors included county level: 1) percentage of 
individuals without health insurance; 2) average travel time to work; and 3) percentage of 
individuals with below high school education.  
 In addition to the SEM factors, we included year of index date as a covariate in all the 
analyses. A small number of individuals received BDT during 2003 to 2006. Hence, we 
combined the index years 2003-2006 into a single level and used the following categories for the 
outcome of BDT: 2003-2006, 2007, 2008, 2009, 2010, and 2011. For mammography, the year of 
index date was categorized into two groups of: before 2009 and after 2009 to examine the impact 
of change in USPSTF guidelines in 2009.51  
3.4.5 Statistical Analyses  
 We analyzed the differences in intra-personal, inter-personal, healthcare, and community 
factors between the DLBCL and the non-cancer patients by using chi-square tests. We used 
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logistic regressions to analyze the relationship of DLBCL diagnosis, PCP visits, and other intra-
personal, inter-personal, healthcare system, and community factors with the receipt of 
mammography screening and BDT. From our preliminary analysis, we found that there were 
significant differences in some characteristics between the DLBCL and non-cancer patients. In 
order to decrease this observed selection bias, we estimated Inverse Probability Treatment 
Weights (IPTW) by conducting logistic regression on DLBCL compared with no cancer with the 
independent variables of age, race/ethnicity, index year, geographic region, diabetes, any heart 
condition, asthma/COPD, arthritis, and depression/anxiety. We used these IPTWs as weights in 
all the unadjusted and adjusted analyses. All analyses were conducted using SAS version 9.4.59 
3.5 Results 
3.5.1 Characteristics of Female DLBCL and Non-Cancer Patients  
 Table 3.1 summarizes the selected characteristics of female DLBCL and non-cancer 
patients above 65 years of age, before and after adjusting with IPTW. Before adjusting with 
IPTW, a higher percentage of Whites compared to Blacks, those aged >70 years compared to 66-
69 years, living in Northeast compared to South, those with arthritis compared to those without 
arthritis, those with any heart condition compared to those without any heart condition, and those 
with asthma/COPD compared to those without asthma/COPD had DLBCL.  
3.5.2 DLBCL and Mammography  
 Table 3.2 summarizes the characteristics of female Medicare beneficiaries by the receipt 
of mammography screening. From chi-square tests, rates of mammography between DLBCL 
(59.8%) and non-cancer patients (60.2%) did not differ. Further, the mammography rates for 
both DLBCL and non-cancer female patients were significantly lower than the Healthy People 
2020 target of 81.1% (both p < .0001). From logistic regression model 1, without adjusting for 
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PCP visits, screening mammography between DLBCL and non-cancer patients did not differ 
(adjusted odds ratio [95%CI]: 0.98 [0.86, 1.13]). However, after adjusting for monthly PCP visits 
in model 2, DLBCL patients were less likely than non-cancer patients to receive mammography 
screening (0.82 [0.71, 0.94]).  
3.5.3 PCP Visits and Mammography 
 From model 2, female beneficiaries with more monthly visits to PCPs were more likely 
to receive mammography screening (1.62 [1.48, 1.77]) (Table 3.2). Further, those aged 70-74 
years compared to 66-69 years, those with other races compared to Whites, those with 
asthma/COPD compared to those without asthma/COPD, those with depression/anxiety 
compared to those without depression/anxiety, those with diabetes compared to those without 
diabetes, tobacco users compared to non-tobacco users, and those living in counties with more 
African Americans compared to counties with less African Americans were less likely to have 
mammography. Also, those living in metro compared to rural regions and those with arthritis 
compared to those without arthritis were more likely to have mammography.  
3.5.4 DLBCL and Bone Density Testing 
 Table 3.3 summarizes the characteristics of female Medicare beneficiaries by the receipt 
of BDT. From chi-square test, the receipt of BDT between DLBCL (18.5%) and non-cancer 
patients (19.6%) did not differ (p = .173). From logistic regression model 3, without adjusting for 
PCP visits, BDT between DLBCL and non-cancer patients did not differ (0.94 [0.84, 1.05]). 
After adjusting for monthly PCP visits in model 4, DLBCL patients were less likely than non-
cancer patients to receive BDT (0.80 [0.71, 0.90]). 
3.5.5 PCP Visits and Bone Density Testing 
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 From model 4, female beneficiaries with more monthly visits to PCPs were more likely 
to receive BDT (1.60 [1.50, 1.71]) (Table 3.3). Further, those aged above 70 years compared to 
66-69 years, African Americans compared to Whites, those living in urban compared to rural 
regions, those with any heart condition compared to those without any heart condition, those 
with depression/anxiety compared to those without depression/anxiety, and those with diabetes 
compared to those without diabetes were less likely to have BDT. Also, those living in South 
compared to North-East, those with index years > 2007 compared to 2003-2006, those with 
arthritis compared to those without arthritis, and those living in counties with more Hispanics 
compared to counties with less Hispanics were more likely to have BDT. 
3.5.6 Mammography and BDT among DLBCL Patients  
 Among female DLBCL patients, more monthly PCP visits was associated with higher 
odds of receiving mammography screening (1.34 [1.17, 1.54]) and BDT (1.47 [1.32, 1.63]). 
Further, among DLBCL patients, those with other races compared to Whites (0.45 [0.26, 0.79]) 
and those living in counties with more travel time (0.44 [0.29, 0.67]) compared to less travel time 
were less likely to have mammography. Also, married women compared to unmarried women 
(2.10 [1.32, 3.36]) were more likely to receive mammography screening. Radiotherapy was not 
significantly associated with mammography (1.04 [0.77, 1.39]). 
 With respect to BDT, more visits to PCPs was associated with higher odds of BDT 
among DLBCL patients (1.46 [1.31, 1.62]). Further, among DLBCL patients, African Americans 
compared to Whites (0.38 [0.19, 0.75]) were less likely and those living in counties with more 
Hispanics compared to counties with less Hispanics (2.67 [1.69, 4.23]) were more likely to 
receive BDT. With respect to DLBCL treatments, patients receiving chemo-immunotherapy 
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were more likely to receive BDT (2.27 [1.42, 3.62]). Stem cell transplant was not significantly 
associated with BDT (1.15 [0.94, 1.41]). 
3.6 Discussion 
 We conducted this study to examine the receipt of mammography and BDT among 
female patients with DLBCL who are at a higher risk of breast cancer and loss of bone density 
than general population. We used a social-ecological model to analyze the relationship of diverse 
personal and environmental factors which can influence the receipt of mammography and BDT 
among female Medicare beneficiaries with DLBCL compared to those without cancer.  
 The rates of mammography need to be increased for both DLBCL and non-cancer female 
patients to meet the Healthy People 2020 target.15 Although DLBCL patients are at a higher risk 
of breast cancer and osteoporosis, without adjusting for PCP visits, there was no significant 
difference in mammography and BDT between DLBCL patients and non-cancer patients. These 
results are inconsistent with previous studies in breast and colorectal cancer patients, which 
found that cancer patients receive more mammograms and BDT than non-cancer patients.35,36,60 
One explanation is that DLBCL is a more aggressive form of cancer and requires more intensive 
treatment than breast and colorectal cancer. Further, we found that DLBCL patients with chronic 
conditions such as diabetes and depression/anxiety were less likely to receive mammography 
screening and BDT. The providers may be prioritizing the acute DLBCL treatment and 
management of other comorbid conditions than preventive screenings in DLBCL patients.  
 After adjusting for PCP visits, DLBCL patients were less likely than non-cancer patients 
to receive mammography and BDT. Further, more PCP visits was associated with higher 
mammography and BDT, which indicates the importance of visiting PCPs for receiving 
preventive screenings.39 Providers should increase the recommendations for mammography and 
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BDT in DLBCL patients, and perhaps DLBCL will benefit the most from seeing their PCP, 
particularly in terms of preventive screenings. DLBCL patients have a favorable prognosis and 
most patients have long survival period after treatment. These patients can benefit by receiving 
preventive screenings to further improve their quality of life. Further, oncologists should 
encourage their patients to visit their PCPs frequently to increase their mammography screening 
and BDT. Although arthritis patients have been found to have lower risk of breast cancer,61-64 we 
found that those with arthritis were more likely to receive mammography. Future studies need to 
examine the reason for higher mammography use among arthritis patients. We found that the 
rates of BDT increased four times after 2006. Even though the rates of BDT remain lower than 
nationally recommended levels, it shows the increase in availability and awareness of BDT in 
recent years among elderly Medicare beneficiaries.  
 The risk of breast cancer and osteoporosis varies with the treatment received among 
DLBCL patients. Female DLBCL patients receiving radiotherapy are at a higher risk of breast 
cancer6 and those receiving stem cell transplant are at a higher risk of osteoporosis.24 However, 
we did not find a significant relationship between radiotherapy and mammography screening. 
Further, the stem cell transplant was not associated with BDT in female DLBCL patients. These 
results indicate the need for higher mammography screening among female DLBCL patients 
receiving radiotherapy and higher BDT among stem cell transplant recipients.  
 The rate of mammography was lower among women aged 70-74 years as compared to 
66-69 years, and BDT was lower among those aged above 70 years as compared to 66-69 years, 
which is consistent with previous studies.36,65 It may be due to belief that preventive services 
may provide little gain in life expectancy for those with higher age. However, we adjusted for 
patients’ other chronic conditions to control for their physical and mental comorbidities. Also, 
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continuing mammography screening in women between 70-74 years of age has been found to be 
cost-effective and can increase survival.65-67 Similarly, BDT can prevent fractures among elderly 
women.68-70 Hence, mammography should be not be stopped for women with 70-74 years of age 
and BDT should be continued among women above 70 years of age as recommended by the 
USPSTF guidelines.  
 Our study has some limitations. We used the HCFA specialty codes given in the SEER-
Medicare dataset to identify the PCP specialties in this study. The HCFA codes have been used 
in previous studies,20,35,71 but these codes may not capture all the visits to different provider 
specialties.72 Our study results are generalizable to female beneficiaries enrolled in fee-for-
service Medicare. A strength of our study is that we used a large nationally representative data of 
patients with newly diagnosed cancer. We examined a comprehensive set of personal and 
contextual factors in our multivariate models. Further, we used a robust study design with IPTW 
adjusted analyses to reduce observed selection bias between women with DLBCL and no cancer.  
3.7 Conclusions 
 There was no significant difference in mammography and BDT between female DLBCL 
patients and women with no cancer. After adjusting for PCP visits, women DLBCL patients were 
less likely than non-cancer patients to receive mammography and BDT. Those with more PCP 
visits were more likely to have mammography and BDT. Further, those between 70-75 years of 
age were less likely to receive mammography and those aged above 70 years were less likely to 
receive BDT than women between 66-69 years of age. Female DLBCL survivors are at a higher 
risk of breast cancer and osteoporosis and need to receive more preventive screenings.  
Implications for Practice and/or Policy 
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 Our study results suggest that providers should increase their recommendations for breast 
cancer screening and BDT in women with DLBCL. Rates of mammograms need to be increased 
for women treated with radiotherapy while BDT should be increased among women who 
received stem cell transplant. Current guidelines recommend breast cancer screening for women 
with Hodgkin’s lymphoma and BDT for stem cell transplant recipients. Similar clinical 
guidelines are required for preventive screenings for women with Non-Hodgkin’s Lymphoma, 
which is four times more common than Hodgkin’s Lymphoma.  
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Table 3.1 Description of Selected Characteristics of Female Medicare Beneficiaries above 65 Years 
of Age with Diffuse Large B-Cell Lymphoma (DLBCL) and No Cancer before and after Inverse 
Probability Treatment Weights. Surveillance Epidemiology and End Results Program (SEER) - 
Medicare 2003-2011. 
  
DLBCL No Cancer 
 
DLBCL   No Cancer  
  
n col% n col% sig IPTW col% IPTW col% 
 
Total 3,029 100.0 11,956 100.0 
   
Age 
 
 
   
*** 
  
 
66-69 yrs. 535 17.7 2,914 24.4 
 
23.0 23.0 
 
>70 yrs. 2,494 82.3 9,042 75.6 
 
77.0 77.0 
Race 
 
 
   
*** 
  
 
White 2,645 87.3 9,877 82.6 
 
83.4 83.6 
 
African American 121 4.0 940 7.9 
 
7.3 7.1 
 
Hispanic 78 2.6 272 2.3 
 
2.3 2.3 
 
Others 185 6.1 867 7.3 
 
7.0 7.0 
Region 
     
*** 
  
 
Northeast 667 22.0 2,371 19.8 
 
20.5 20.3 
 
South 705 23.3 3,207 26.8 
 
25.8 26.1 
 
North-central 401 13.2 1,448 12.1 
 
12.3 12.3 
 
West 1,256 41.5 4,930 41.2 
 
41.4 41.3 
Rural Urban 
       
 
Metro 2,514 83.0 9,926 83.0 
 
83.1 83.1 
 
Urban 455 15.0 1,791 15.0 
 
15.0 14.9 
 
Rural 60 2.0 239 2.0 
 
2.0 2.0 
Index year 
    
** 
  
 
2003 341 11.3 1,409 11.8 
 
11.7 11.7 
 
2004 349 11.5 1,325 11.1 
 
11.5 11.2 
 
2005 334 11.0 1,277 10.7 
 
10.9 10.8 
 
2006 326 10.8 1,158 9.7 
 
10.1 9.9 
 
2007 336 11.1 1,207 10.1 
 
10.2 10.3 
 
2008 357 11.8 1,245 10.4 
 
10.6 10.7 
 
2009 331 10.9 1,320 11.0 
 
11.0 11.0 
 
2010 323 10.7 1,403 11.7 
 
11.4 11.5 
 
2011 332 11.0 1,612 13.5 
 
12.5 13.0 
         
Arthritis 
    
*** 
   
 
Yes 1,125 37.1 3,895 32.6  33.3 33.5 
 
No 1,904 62.9 8,061 67.4  66.7 66.5 
Any Heart Condition     ***    
 
Yes 1,227 40.5 4,422 37.0  38.2 37.7 
 
No 1,802 59.5 7,534 63.0  61.8 62.3 
Asthma/COPD     ***    
 
Yes 643 21.2 2,202 18.4  19.2 19.0 
 
No 2,386 78.8 9,754 81.6  80.8 81.0 
Depression/Anxiety     ***    
 
Yes 417 13.8 1,741 14.6  14.8 14.4 
 
No 2,612 86.2 10,215 85.4  85.2 85.6 
Diabetes     ***    
 
Yes 892 29.4 3,443 28.8  29.7 28.8 
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No 2,137 70.6 8,513 71.2  70.3 71.2 
Note. Based on 3,029 female Medicare beneficiaries with Diffuse Large B-Cell Lymphoma and a random sample of 
11,956 female beneficiaries without any cancer who resided in SEER areas. Weighted percentages were derived 
with using inverse probability treatment weights. COPD: Chronic Obstructive Pulmonary Disease; Sig. significance 
level. 
***p<.001 **.001< p<.01    
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Table 3.2 Unadjusted Differences and Adjusted Odds Ratios for Screening Mammography by Selected Characteristics of 
Female Medicare Beneficiaries between 66-74 years of age after Inverse Probability Treatment Weights. Surveillance 
Epidemiology and End Results Program (SEER) - Medicare 2003-2011. 
   
Screening Mammography 
   
Yes No 
 
Model 1 Model 2 
  
n IPTW row% Sig. AOR 95% CI Sig. AOR 95% CI Sig. 
 
Total 
 
4,103 2,720 
       
DLBCL 
          
 
Yes 1,137 59.8 40.2 
 
0.98 [0.86, 1.13] 
 
0.82 [0.71, 0.94] ** 
 
No Cancer 5,686 60.2 39.8 
 
Ref. 
  
Ref. 
  
Mean Monthly PCP Visits 0.43 0.80 0.54 *** NA 
1.62 [1.48, 1.77] *** 
Age 
    
*** 
      
 70-74 yrs. 3,374 57.5 42.5  0.80 [0.72, 0.89] *** 0.80 [0.72, 0.89] *** 
 
66-69 yrs. 3,449 62.8 37.2  Ref.   Ref.   
Race 
    
*** 
      
 
African American 541 58.7 41.3 
 
0.97 [0.79, 1.18] 
 
0.97 [0.79, 1.18] 
 
 
Hispanic 149 60.3 39.7 
 
1.07 [0.75, 1.53] 
 
1.10 [0.76, 1.58] 
 
 
Others 512 49.4 50.6 
 
0.59 [0.48, 0.72] *** 0.57 [0.47, 0.70] *** 
 White 5,621 61.3 38.7  Ref.   Ref.   
Region 
           
 
South 1,903 59.5 40.5 
 
1.17 [0.98, 1.41] 
 
1.12 [0.93, 1.35] 
 
 
North-central 803 59.7 40.3 
 
0.97 [0.80, 1.19] 
 
0.92 [0.75, 1.12] 
 
 
West 2,893 60.5 39.5 
 1.13 [0.95, 1.34]  1.10 [0.92, 1.31]  
 Northeast 1,224 60.4 39.6  Ref.   Ref.   
Rurality 
          
 
Metro 5,612 60.5 39.5 
 
1.62 [1.09, 2.40] * 1.57 [1.05, 2.35] * 
 
Urban 1,080 59.2 40.8 
 
1.42 [0.96, 2.09] 
 
1.35 [0.91, 2.01] 
 
 
Rural 131 51.9 48.1 
 
Ref. 
  
Ref. 
  
Arthritis 
          
 
Yes 1,964 61.4 38.6 
 
1.19 [1.06, 1.34] ** 1.15 [1.02, 1.29] * 
 
No 4,859 59.6 40.4 
 
Ref. 
  
Ref. 
  
Any Heart Condition 
   
* 
      
 
Yes 1,974 58.0 42.0 
 
1.00 [0.88, 1.12] 
 
0.92 [0.82, 1.04] 
 
 
No 4,849 61.0 39.0 
 
Ref. 
  
Ref. 
  
Asthma/COPD 
   
*** 
      
 
Yes 1,236 54.5 45.5 
 
0.82 [0.71, 0.93] ** 0.78 [0.68, 0.90] *** 
 
No 5,587 61.4 38.6 
 
Ref. 
  
Ref. 
  
Depression/Anxiety 
   
*** 
      
 
Yes 1,000 54.9 45.1 
 
0.78 [0.67, 0.90] *** 0.71 [0.61, 0.82] *** 
 
No 5,823 61.0 39.0 
 
Ref. 
  
Ref. 
  
Diabetes 
   
*** 
      
 
Yes 2,012 56.5 43.5 
 
0.86 [0.77, 0.97] * 0.80 [0.71, 0.90] *** 
 
No 4,811 61.7 38.3 
 
Ref. 
  
Ref. 
  
Tobacco Use 
   
*** 
      
 
Yes 214 41.3 58.7 
 
0.48 [0.36, 0.65] *** 0.46 [0.34, 0.62] *** 
 
No 6,609 60.7 39.3 
 
Ref. 
  
Ref. 
  
Index Year 
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Table 3.2 Unadjusted Differences and Adjusted Odds Ratios for Screening Mammography by Selected Characteristics of 
Female Medicare Beneficiaries between 66-74 years of age after Inverse Probability Treatment Weights. Surveillance 
Epidemiology and End Results Program (SEER) - Medicare 2003-2011. 
 
After 2009 1,990 59.7 40.3 
 
0.97 [0.86, 1.08] 
 
0.96 [0.86, 1.08] 
 
 Before 2009 4,833 60.3 39.7  Ref.   Ref.   
County% Blacks 
   
** 
      
 
4.45 1,686 60.8 39.2 
 
0.87 [0.74, 1.02] 
 
0.85 [0.72, 1.00] 
 
 
10.09 1,701 57.2 42.8 
 
0.79 [0.66, 0.95] * 0.78 [0.65, 0.93] ** 
 
31.12 1,710 58.9 41.1 
 
0.80 [0.65, 0.97] * 0.79 [0.64, 0.97] * 
 1.22 1,726 63.7 36.3  Ref.   Ref.   
County% Less than High 
School Education    
*** 
      
 
12.48 1,697 63.3 36.7 
 
0.98 [0.84, 1.14] 
 
0.98 [0.84, 1.15] 
 
 
16.71 1,731 59.0 41.0 
 0.80 [0.69, 0.94] ** 0.82 [0.70, 0.96] * 
 
25.37 1,698 54.6 45.4 
 
0.68 [0.57, 0.82] *** 0.67 [0.56, 0.80] *** 
 8.48 1,697 63.7 36.3  Ref.   Ref.   
Note. Based on 1,137 female Medicare beneficiaries with Diffuse Large B-Cell Lymphoma and a random sample of 5,686 
female beneficiaries without any cancer between 66-74 years of age who resided in SEER areas. Weighted percentages 
were derived with using inverse probability treatment weights. COPD: Chronic Obstructive Pulmonary Disease; PCP: 
Primary care physician; Sig. significance level. 
***p<.001 **.001< p<.01 *.01< p<.05 
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Table 3.3 Unadjusted Differences and Adjusted Odds Ratios for Bone Density Testing by Selected Characteristics of Female 
Medicare Beneficiaries above 65 years of Age after Inverse Probability Treatment Weights. Surveillance Epidemiology and End 
Results Program (SEER) - Medicare 2003-2011. 
  
Bone Density Testing 
   
Yes No 
 
Model 3 Model 4 
  
n IPTW row% Sig. AOR 95% CI Sig. AOR 95% CI Sig. 
 
Total 14,985 19.5 80.5 
       DLBCL 
          
 
Yes 3,029 18.5 81.5 
 
0.94 [0.84, 1.06] 
 
0.80 [0.71, 0.90] *** 
 
No Cancer 11,956 19.6 80.4 
 
Ref. 
  
Ref. 
  
Mean Monthly PCP Visits 
0.46 0.95 0.60 *** NA 1.60 [1.50, 1.71] *** 
Age 
    
*** 
      
 
>70 yrs. 11,536 17.3 82.7 
 
0.64 [0.58, 0.71] *** 0.61 [0.55, 0.68] *** 
 66-69 yrs. 3,449 26.2 73.8  Ref.   Ref.   
Race 
    
*** 
      
 
African American 1,061 12.0 88.0 
 
0.51 [0.41, 0.62] *** 0.51 [0.41, 0.63] *** 
 
Hispanic 350 18.6 81.4 
 
0.76 [0.56, 1.03] 
 
0.81 [0.60, 1.10] 
 
 
Others 1,052 19.7 80.3 
 
0.90 [0.75, 1.07] 
 
0.89 [0.74, 1.06] 
  White 12,522 20.0 80.0  Ref.   Ref.   
Region 
           
 
South 3,912 18.4 81.6 
 
1.39 [1.17, 1.66] *** 1.38 [1.16, 1.66] *** 
 
North-central 1,849 18.4 81.6 
 
1.34 [1.10, 1.63] ** 1.27 [1.03, 1.55] * 
 
West 6,186 20.5 79.5 
 
0.94 [0.82, 1.08] 
 
0.94 [0.82, 1.08] 
  Northeast 3,038 18.9 81.1  Ref.   Ref.   
Rural / Urban 
   
*** 
      
 
Metro 12,440 20.0 80.0 
 
0.86 [0.61, 1.19] 
 
0.80 [0.57, 1.12] 
 
 
Urban 2,246 16.0 84.0 
 
0.68 [0.49, 0.96] * 0.65 [0.46, 0.92] * 
 
Rural 299 19.5 80.5 
 
Ref. 
  
Ref. 
  
Arthritis 
   
*** 
      
 
Yes 5,020 21.2 78.8 
 
1.29 [1.17, 1.42] *** 1.22 [1.10, 1.34] *** 
 
No 9,965 18.5 81.5 
 
Ref. 
  
Ref. 
  
Any Heart Condition 
          
 
Yes 5,649 18.6 81.4 
 
0.98 [0.89, 1.08] 
 
0.90 [0.81, 0.99] * 
 
No 9,336 19.9 80.1 
 
Ref. 
  
Ref. 
  
Asthma/COPD 
          
 
Yes 2,845 19.0 81.0 
 
0.99 [0.88, 1.11] 
 
0.94 [0.84, 1.06] 
 
 
No 12,140 19.5 80.5 
 
Ref. 
  
Ref. 
  
Depression/Anxiety 
          
 
Yes 2,158 19.2 80.8 
 
0.85 [0.75, 0.96] * 0.77 [0.67, 0.87] *** 
 
No 12,827 19.4 80.6 
 
Ref. 
  
Ref. 
  Diabetes 
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Table 3.3 Unadjusted Differences and Adjusted Odds Ratios for Bone Density Testing by Selected Characteristics of Female 
Medicare Beneficiaries above 65 years of Age after Inverse Probability Treatment Weights. Surveillance Epidemiology and End 
Results Program (SEER) - Medicare 2003-2011. 
 
Yes 4,335 19.0 81.0 
 
0.87 [0.79, 0.97] ** 0.81 [0.73, 0.90] *** 
 
No 10,650 19.5 80.5 
 
Ref. 
  
Ref. 
  
Index Year 
   
*** 
      
 
2007 1,543 28.6 71.4 
 
4.84 [4.15, 5.63] *** 4.79 [4.10, 5.59] *** 
 
2008 1,602 31.2 68.8 
 
5.45 [4.69, 6.33] *** 5.44 [4.68, 6.33] *** 
 
2009 1,651 27.3 72.7 
 
4.52 [3.88, 5.26] *** 4.49 [3.85, 5.23] *** 
 
2010 1,726 28.3 71.7 
 
4.63 [3.99, 5.37] *** 4.50 [3.87, 5.23] *** 
 
2011 1,944 28.0 72.0 
 
4.47 [3.86, 5.17] *** 4.38 [3.78, 5.08] *** 
 
2003, 2004, 2005, 
2006 6,519 7.5 92.5  Ref.   Ref.   
County% Hispanics 
   
*** 
      
 
6.81 3,772 19.9 80.1 
 
1.29 [1.10, 1.51] ** 1.27 [1.08, 1.49] ** 
 
17.00 3,656 19.9 80.1 
 
1.42 [1.17, 1.71] *** 1.43 [1.18, 1.74] *** 
 
42.99 3,791 22.9 77.1 
 
2.05 [1.62, 2.59] *** 2.09 [1.65, 2.65] *** 
 2.23 3,766 14.7 85.3  Ref.   Ref.   
County% Less Than High School 
          
 
12.43 3,829 19.5 80.5 
 
0.96 [0.83, 1.10] 
 
0.94 [0.82, 1.08] 
 
 
16.71 3,691 19.0 81.0 
 
0.85 [0.73, 0.99] * 0.84 [0.72, 0.98] * 
 
25.20 3,721 19.3 80.7 
 
0.78 [0.65, 0.94] ** 0.75 [0.62, 0.90] ** 
 8.46 3,744 19.7 80.3  Ref.   Ref.   
Note. Based on 3,029 female Medicare beneficiaries with Diffuse Large B-Cell Lymphoma and a random sample of 11,956 
female beneficiaries without any cancer who resided in SEER areas. Weighted percentages were derived with using inverse 
probability treatment weights. COPD: Chronic Obstructive Pulmonary Disease; PCP: Primary care physician; Sig. 
significance level. 
***p<.001 **.001< p<.01 *.01< p<.05
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Appendix 3.1 Flowchart of Sample Selection for Female Medicare Beneficiaries with Diffuse Large B-Cell 
Lymphoma.  
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Appendix 3.2 Flowchart of Sample Selection for Female Medicare Beneficiaries with No Cancer. 
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Chapter 4: Impact of Diffuse Large B-Cell Lymphoma on the Costs of Chronic Conditions 
in Elderly Medicare Beneficiaries 
 
4.1 Abstract 
 Background. Newly diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) can increase 
the cost burden of chronic conditions in elderly individuals. However, there is a lack of research 
on change in costs of chronic conditions during DLBCL diagnosis, treatment, and follow-up as 
compared to those without cancer. Objective. We examined the cost of common chronic 
conditions and total cost among 5,455 DLBCL patients >65 years of age as compared to 14,770 
individuals without cancer during a 3-year period of DLBCL diagnosis, treatment, and follow-
up. Methods. We used a retrospective longitudinal study design with Surveillance, 
Epidemiology, and End Results (SEER)-Medicare 2002-2013 data to estimate the costs of care 
during 6 months’ intervals (pre-diagnosis: t1, t2 and post-diagnosis: t3, t4, t5, t6). All costs were 
adjusted to 2013 constant dollars. Results. The difference in total cost between DLBCL and non-
cancer patients increased substantially from t1 ($468.8) to t3 (treatment period: $60,746.1) and t6 
($6,614.8). DLBCL patients had a higher cost of heart conditions; however, they had 
significantly lower costs of hypertension, asthma/chronic obstructive pulmonary disease, any 
mental illness, and diabetes than non-cancer patients (all p< .001). Conclusions. DLBCL patients 
incurred high total cost of care during the treatment period. The cardiotoxicity of DLBCL 
treatment may have increased the cost of heart conditions. DLBCL patients might be receiving 
less healthcare services for other conditions leading to lower short term costs of other common 
chronic conditions. Future studies are recommended to investigate the cost-effectiveness of 
increasing the quality of care for chronic conditions among DLBCL patients. 
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4.2 Introduction 
 Advances in early detection and treatment of cancer among elderly individuals have led 
to a substantial cost burden to Medicare, which is projected to further increase in the next 
decade.1,2 The cancer specific and total costs of care vary widely according to the tumor site and 
phase of care.1 Brain, pancreatic, gastric, esophageal, ovarian, and liver cancers account for 
highest costs (> $40,000), as compared to breast, prostate, urinary bladder, and skin cancers.1 
Non-Hodgkin’s Lymphoma is the most common blood cancer in the United States and is 
commonly diagnosed in an aggressive form.3 The total annual cost of care for patients with 
lymphoma has been found to be highest during the first 12 months after diagnosis (men: 
$27,686, women: $28,882) and last year of life ($45,760, $51,763) as compared to annual cost in 
between these phases ($3,993, $4,536).1 To date, no studies have compared the costs of care for 
patients with lymphoma to non-cancer controls. 
 Medicare spending is further compounded for beneficiaries who have chronic conditions 
in addition to cancer,4 which is ten times more common among elderly as compared to younger 
individuals.5-7 For example, elderly renal cell cancer patients had higher one year Medicare costs 
due to hyperlipidemia ($2745) and anemia ($2167) in 2005 as compared to cancer patients 
without hyperlipidemia and anemia.8 Further, the additional 6-month cost of chronic conditions 
among cancer survivors included $3418-$4385 for heart conditions; $5040-$8155 for respiratory 
conditions; $7483-$7714 for diabetes; and $8004-$11,009 for mental conditions in Medicaid 
enrollees in three states (Georgia, Maine, or Illinois) in 2003. Existing studies have examined the 
additional cost burden of chronic conditions in patients with cancers such as colon9, renal cell8, 
oral10, ovarian11, and thyroid12 cancers as compared to those without any chronic condition. 
However, there is a dearth of evidence for the impact of cancer on the costs of chronic conditions 
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before cancer diagnosis, during cancer treatment, and at follow-up periods, as compared to those 
without cancer. Aggressive cancers such as Diffuse Large B-Cell Lymphoma (DLBCL) can have 
varying effects on the costs of different chronic conditions, particularly in light of treatment 
toxicities, which has not been previously explored. 
 DLBCL is the most common subtype of Non-Hodgkin’s lymphoma13 and requires 
intensive treatment regimens such as chemo-immunotherapy and stem cell transplant.14,15 
Chemotherapy with Doxorubicin is associated with cardiotoxicity16 while stem cell transplant 
increases the risk of osteoporosis and fractures17,18 in DLBCL patients. These treatments can 
specifically increase the cost of heart conditions, arthritis, and osteoporosis in DLBCL patients. 
However, previous studies have found that patients with colorectal cancer were less likely to 
receive care for heart conditions, diabetes, and COPD,19,20 which can decrease the short term cost 
but increase the long term cost of these chronic conditions. Hence, the diagnosis and treatment of 
DLBCL can selectively increase or decrease the cost of some chronic conditions, which has 
implications for resource allocation and bundled payments for DLBCL. 
 The Centers for Medicare and Medicaid Services (CMS) launched a new bundled 
payment model for cancer care called the ‘Oncology Care Model’ in 2016.21 This model will be 
implemented over next five years and will reward participating physician group practices for 
reducing the costs of care while meeting the benchmark quality measures. It is important to 
examine the total costs and the costs of common chronic conditions among DLBCL patients to 
inform the target costs for performance-based payments under this model. The study findings 
will also highlight the potential benefits of early prevention, detection, and chronic disease 
management efforts for DLBCL patients.  
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4.3 Theoretical Framework 
 To date, most existing studies dealing with costs of care have examined the individual 
characteristics including gender, race, age, education, and income, while less attention has been 
paid to the societal or contextual factors.22-2627  Societal and environmental factors such as 
county level racial/ethnic composition, availability of healthcare facilities, and transportation 
have a significant impact on healthcare utilization, thereby affecting the costs of care.28-31 For 
example, blacks had higher healthcare utilization when they lived in a county with a higher 
percentage of blacks.29 Higher availability of primary care physicians and non-rural area of 
residence were associated with higher use of preventive services.32 Per-capita spending by 
Medicare varies significantly across the different states as well.33  
 Since the costs of care are a result of decisions made at individual, societal, and 
organizational levels,34 we used a multilevel Socio Ecological Model (SEM) as the theoretical 
framework to analyze the cost of chronic conditions and total cost among DLBCL patients.35,36 
Previous studies have used the SEM to examine the healthcare utilization of patients with or 
without cancer.37-41 According to the SEM, the utilization of healthcare services is determined by 
following individual and contextual factors35,36,42 : 1) Intra-personal factors: include unique 
socio-demographic characteristics of individuals such as age, sex, race, stage of DLBCL, and 
DLBCL treatments; 2) Inter-personal factors: consist of racial/ethnic composition of county 
measured by percentage of Blacks and Hispanics in the county; 3) Healthcare system factors: 
include the availability of hospitals and physicians in the county which facilitate the use of 
healthcare services; and 4) Community factors: consist of the surrounding geographical area 
including SEER region, urban/rural region, and county level poverty, education, and average 
travel time.36,37,43 Therefore, the purpose of this study is to examine the costs of care for common 
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chronic conditions and total costs among elderly Medicare beneficiaries with DLBCL over a 3-
year study period as compared to beneficiaries without any cancer. 
4.4 Methods 
4.4.1 Study Design 
 This study used a retrospective longitudinal study design with 12 month pre-index and 24 
month post-index phases. For DLBCL patients, we defined the pre-index and post-index phases 
using the DLBCL diagnosis as the index date. For non-cancer patients, we used a random 
inpatient or outpatient Medicare claim service date to identify the pre-index and post-index 
phases. We divided the pre-index and post-index phases into six months’ intervals (t1-t6). For 
DLBCL patients, the pre-index phase consisted of baseline (t1) and pre-diagnosis (t2) and post-
index phase comprised of treatment (t3), post-treatment (t4), short follow-up (t5), and long 
follow-up (t6) periods.     
4.4.2 Data Sources 
 We utilized the following data sources for this study: 1) Surveillance, Epidemiology and 
End Results Program (SEER) data: SEER is an epidemiologic cancer surveillance system which 
collects information on patients with incident cancers residing in 20 cancer registry areas (Alaska 
Native Tumor Registry, Arizona Indians, Cherokee Nation-Oklahoma, Connecticut, Detroit, 
Atlanta-Georgia, Greater California, Greater Georgia, Hawaii, Iowa, Kentucky, Los Angeles, 
Louisiana, New Jersey, New Mexico, Rural Georgia, San Francisco-Oakland, San Jose-
Monterey, Seattle-Puget Sound, and Utah).44 SEER contains data on cancer patient’s 
demographic characteristics, site and date of cancer diagnosis, stage and grade of cancer (e.g., 
Ann Arbor DLBCL stage, and region and rurality of resident area. 2) Random sample of 5% 
Medicare beneficiaries: We used this data to derive a comparison group of Medicare 
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beneficiaries without any cancer (except basal cell carcinoma) who resided in SEER areas. 3) 
Medicare claims data: We linked the Medicare claims data with SEER registry data to obtain 
detailed information on use of healthcare services and their costs. 4) Area Health Resource File 
(AHRF): We used the publicly available AHRF data45 to obtain information on the county level 
inter-personal, healthcare system, and community factors.  
4.4.3 Study Sample   
 We included 5,455 DLBCL patients who were aged >66 years with a primary diagnosis 
of DLBCL (International Classification of Diseases for Oncology - Third Revision (ICD-O-
3)/World Health Organization 2008 codes: 13, 14, 15, 16) during 2003-2011. We included 
patients who had only one primary cancer (except basal cell carcinoma) and whose cancer was 
not diagnosed from autopsy. For the comparison group, we selected a 10% random sample of 
Medicare beneficiaries with >66 years of age from the non-cancer patient dataset who resided in 
SEER areas and did not have any cancer (except basal cell carcinoma).  
 We applied the following exclusion criteria to both DLBCL and non-cancer patients: 1) 
those with End Stage Renal Disease (ESRD); 2) not alive during the study period; 3) enrolled in 
managed care plans during study period; 4) not continuously enrolled in Medicare parts A and B; 
5) not having any Primary Care Physician (PCP) visit during the study period; and 6) having 
missing values for age, sex, race, region, or ESRD. 
4.4.4 Measures  
 Dependent variables. We analyzed the following direct medical costs of care as 
dependent variables: 1) disease specific and overall cost of the following chronic conditions – 
arthritis, asthma/COPD, any heart condition, any mental illness, diabetes, hypertension, 
hyperlipidemia, and osteoporosis. We used the payments made by Medicare for inpatient (Part 
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A), outpatient and physician services (Part B), and home health agency (HHA) services for these 
chronic conditions to estimate these costs; 2) total cost of care including all payments made by 
Medicare for part A, part B, HHA, and Durable Medical Equipment (DME) claims for any health 
condition.46 Similar to previous studies,1,47 we used payments made by Medicare, instead of 
billed charges, to measure the true cost of care. All costs were adjusted to 2013 dollars by using 
the consumer price index for medical care.48  
 Cancer Status. The key independent variable for this study was the diagnosis of DLBCL 
as compared to having no cancer. The DLBCL diagnosis belonged to the domain of intra-
personal factors from the SEM.  
SEM Independent Variables 
 Our study included both time varying and time invariant factors. The independent 
variables of tobacco use and chronic conditions (arthritis, diabetes, any heart condition, 
depression/anxiety, and asthma/COPD) were time varying and were measured during each time 
interval from t1 to t6. The intra-personal factors of cancer treatments (chemo-immunotherapy, 
radiotherapy, and stem cell transplant) for DLBCL patients were measured during the post-index 
phase of two years. All other intra-personal, inter-personal, healthcare system, and community 
factors were measured during the one year pre-index phase.  
 Intra-personal factors consisted of: 1) age at index date; 2) sex; 3) race; 4) arthritis 
(osteoarthritis or rheumatoid arthritis); 5) diabetes; 6) any heart condition (cardiac arrhythmia, 
coronary artery disease, or congestive heart failure); 7) depression or anxiety; and 8) respiratory 
condition (Asthma or COPD). The following factors were measured for DLBCL patients only: 1) 
Ann Arbor DLBCL stage (stage I, II, III or IV); 2) chemo-immunotherapy with Rituximab, 
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Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone (R-CHOP); 3) radiotherapy; and 
4) stem cell transplantation. 
 Inter-personal factors included 1) racial/ethnic isolation measured by percentage of 
Blacks and Hispanics in the county; and 2) social/cultural cohesion estimated by the percentage 
of non-English speaking individuals above 18 years of age in the county. 
 Healthcare system factors consisted of county level: 1) primary care physician shortage 
area (Whole County, part of county, or no shortage); 2) number of hospitals per 10,000 
individuals above 65 years of age; and 3) number of Federal Qualified Health Centers (FQHC) 
per 10,000 individuals above 65 years of age. 
 Community factors included county level: 1) geographic region (Northeast, South, 
North-Central, or West); 2) rurality: We used urban/rural recode to classify region into metro 
(counties in metro areas with 250,000 to 1,000,000 population), urban (counties with urban 
population of 2,500 to 20,000 population), and rural (counties with completely rural or <2,500 
urban population)44; 3) percentage of individuals between 18 and 64 years of age without health 
insurance; 4) percentage of individuals with below high school education; and 5) average travel 
time to work. In addition to the SEM variables, we included time and index year as independent 
variables.  
4.4.5 Statistical Analyses  
 We conducted unadjusted analyses of non-normal cost data by using non-parametric 
tests.49 Kruskal-Wallis rank tests analyzed the unadjusted differences in total cost and cost of all 
chronic conditions among DLBCL and non-cancer patients.50 Further, we utilized repeated 
measures Friedman test to analyze the unadjusted differences in cost between DLBCL and non-
cancer patients during t1-t6.51 For adjusted analyses, the population-averaged Generalized 
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Estimating Equations (GEE) with gamma distribution and log link analyzed the skewed cost 
data.52 We used an unstructured correlation structure with GEE to account for the repeated 
measures of costs among patients during t1-t6.52 Also, to reduce the observed selection bias 
between DLBCL and non-cancer patients, we utilized Inverse Probability Treatment Weights 
(IPTW) in all the adjusted analyses with GEE. We also analyzed the interaction between 
patients’ race/ethnicity and racial/ethnic composition of county to elucidate its impact on the cost 
of chronic conditions in this study. All analyses were conducted using SAS version 9.4.53 
4.5 Results 
4.5.1 Costs of Care by Characteristics of DLBCL Patients 
 The description of cost of chronic conditions and total overall cost during 12 months after 
cancer diagnosis in DLBCL patients is presented in Table 4.1. The DLBCL patients had 
substantial total annual cost ($80,220.9) after diagnosis. Those having depression/anxiety 
($97,098.7), asthma/COPD ($92,341.2), any heart condition ($88,840.2), diabetes ($88,311.7), 
and arthritis ($87,501.7) had higher average total cost as compared to those with no 
depression/anxiety ($75,766.9), no asthma/COPD ($74,910.2), no heart condition ($64,326.2), 
no diabetes ($75,748.4), and no arthritis ($76,782.0). The total annual cost of common chronic 
conditions was $3,099.7 after cancer diagnosis. Tobacco users had a significantly higher cost of 
chronic conditions ($4,424.5) than non-tobacco users ($3,017.7). Further, beneficiaries between 
75-79 years of age as compared to 66-69 years, those living in North-East as compared to South, 
those living in metro as compared to rural area, and those with a chronic condition as compared 
to those without chronic condition had higher cost of chronic conditions and total costs of care. 
4.5.2 Total Costs for DLBCL Patients 
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 Mean net costs of care (i.e., the difference in total cost between DLBCL and individuals 
without cancer) are presented in Table 4.2. DLBCL patients had significantly higher costs than 
non-cancer patients from t1 to t6. The 6-month cost difference between DLBCL and non-cancer 
patients increased sharply from baseline, t1 ($468.8) to treatment period, t3 ($60,746.1) and 
remained higher during long follow-up period, t6 ($6,614.8). 
4.5.3 Costs of Chronic Conditions for DLBCL Patients 
 The change in cost of heart conditions and cost of all chronic conditions among 
beneficiaries with DLBCL and those without cancer are presented in Figure 4.1. The change in 
cost of heart conditions had the most impact on the cost of all chronic conditions, as both 
significantly increased during the treatment period and decreased after the treatment was over. 
The cost of all chronic conditions of DLBCL patients remained greater than baseline during the 
follow-up periods. For beneficiaries without cancer, the cost of chronic conditions showed a 
random increase during t2 and then constantly increased from t3 to t6. One explanation is the 
increasing age of Medicare beneficiaries, and hence, an increase in the diagnosis and treatment 
of chronic conditions.  
 The cost of chronic conditions was moderately higher among DLBCL patients as 
compared to those without cancer (Table 4.2). The largest difference in total cost of all chronic 
conditions was during t3 ($768.3). The cost of heart conditions accounted for the majority of cost 
of chronic care among DLBCL patients (about 60%) (Table 4.3). The net cost of heart conditions 
among DLBCL patients increased from t1 ($148.3) to t3 ($663.9) and then decreased during t6 
($231.3). The cost of arthritis was lower among DLBCL patients as compared to patients without 
cancer from t2 to t6. Also, the cost of hypertension and diabetes was lower among DLBCL 
patients as compared to non-cancer patients during t1, t2, and t6 (Table 4.3).  
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4.5.4 Impact of DLBCL on Cost of Chronic Conditions 
 From adjusted analysis, DLBCL patients had $586.8 higher adjusted cost of all chronic 
conditions than patients without cancer (Table 4.4). The cost of chronic conditions was 
significantly higher during t2, t3, t4, t5 and t6 as compared to t1. Among DLBCL patients, those 
receiving radiotherapy had lower cost of chronic conditions.  
 With regard to the intra-personal factors, beneficiaries with age 70-74, 75-79, or >80 
years as compared to 66-69 years, Blacks as compared to Whites, and tobacco users as compared 
to non-tobacco users had significantly higher cost of chronic conditions. Further, females as 
compared to males and those living in West or South as compared to North-East had 
significantly lower costs of chronic conditions.  
 For county level factors, those living in counties with shortage of PCPs as compared to 
counties with no shortage, counties with higher average travel time to work as compared to 
counties with lower travel time, and counties with lower education level as compared to counties 
with higher education level had higher cost of chronic conditions. There was a significant 
interaction between patient’s race and the racial composition of the county. Black Medicare 
beneficiaries living in a county with higher prevalence of Blacks had higher costs of chronic 
conditions.  
4.6 Discussion 
 In this study, we used SEER-Medicare data to examine the costs of common chronic 
conditions and total cost of care among elderly Medicare beneficiaries with DLBCL as compared 
to those without cancer. The net total costs of care increased substantially during the treatment 
period among DLBCL patients, which was comparable to brain and pancreatic cancers.1 High 
cost of care for DLBCL patients may be attributed to stem cell transplantation which was 
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received by 64% of DLBCL patients and costs about $99,899 (autologous) to $203,026 
(allogeneic) for 100 days of treatment.54,50 With an aging US population and increased life 
expectancy, the cost burden of DLBCL to the Medicare program may increase further in the 
future.  
 Outpatient costs constituted the largest component of the total cost of care for DLBCL. 
This result is contrary to other cancers such as colorectal, cervical, and renal cancers for which 
hospitalizations account for the largest share of cost estimates.1 The reason for high proportion of 
outpatient costs is that chemo-immunotherapy or radiotherapy are the main treatments for 
DLBCL which are provided in hospital outpatient or office/clinic settings.55-57 Further 
exploration of the other components of costs such as prescription drugs for DLBCL patients is 
warranted.  
 The impact of DLBCL on the costs of chronic conditions varied by the specific chronic 
disease reflecting differences in the impact of DLBCL and its treatment on prognosis and care of 
different chronic conditions. DLBCL patients had significantly higher cost of heart conditions 
than non-cancer patients. The cost of heart conditions doubled during the treatment period and 
accounted for the majority of cost of chronic conditions. One explanation is the use of 
Doxorubicin based chemotherapy which causes cardiotoxicity such as development of 
congestive heart failure and cardiomyopathy in lymphoma patients.58,59 Treatment related 
cardiotoxicity can cause significant morbidity and mortality in lymphoma patients,60,61 which can 
lead to higher long term costs. The bundled payment for cancer care under the CMS’s Oncology 
Care Model should include the cost of heart conditions in DLBCL patients. Appropriate 
management of heart conditions in DLBCL patients is critical and can reduce the long term costs 
of care. Some primary prevention measures for high-risk patients include the use of dexrazoxane 
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and the administration of doxorubicin in liposomal form or as continuous infusion.62 Also, 
biomarkers and imaging studies can be used for early detection and treatment of heart conditions 
in DLBCL patients.62  
 We found that among DLBCL patients, the cost of arthritis decreased over time from 
DLBCL diagnosis to treatment and follow-up periods. Further, DLBCL patients had lower costs 
of common conditions such as hypertension, asthma/COPD, mental illness, and diabetes during 
the baseline and follow-up periods. There was no significant difference in the cost of arthritis, 
hyperlipidemia, and osteoporosis in DLBCL patients as compared to non-cancer patients. These 
results may reflect the lower receipt of care for these chronic conditions as found in previous 
studies.19,20 This is concerning because DLBCL treatment increases the risk of osteoporosis, 
fractures, and mental illness.18,63 Further research is required to investigate the impact of DLBCL 
on the quality of care of these chronic conditions and their association with overall survival. The 
inclusion of quality measures for chronic conditions in cancer care models might improve 
chronic care and reduce long term costs of DLBCL patients.  
 Our findings suggest that costs of chronic care among cancer patients are influenced by 
both individual and community level factors. We identified county level factors such as racial 
composition, shortage of primary care, education level, and travel time were associated with cost 
of chronic care. Blacks living in community with higher prevalence of blacks had higher cost of 
chronic conditions. The efforts to reduce the costs of chronic conditions for cancer patients 
should move beyond individual level factors and focus on the community level factors as well.  
 Our study has some limitations. We included Medicare beneficiaries with index date in 
2003-2011. The Medicare Part D data, which provides prescription drug coverage, was available 
from 2007. Hence, the majority of our study population was not enrolled in Part D, and we could 
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not include the cost of medications in our cost estimates. Future studies with cost of prescription 
drugs may further elucidate the impact of cancer on cost of chronic conditions. We also did not 
include the out-of-pocket cost or co-payments by Medicare enrollees, which have been estimated 
to be approximately 7% for Medicare Part A and 20% for Part B.1 Our study results may be 
applicable to fee-for-service Medicare enrollees only. 
 The strengths of this study include the use of a large population-based data for patients 
with newly diagnosed cancer. Since Medicare is the primary insurance payer for individuals 
above 65 years of age, SEER-Medicare dataset provides the most complete information on the 
use and cost of health services by beneficiaries with cancer. The direct medical cost estimates of 
specific chronic conditions and DLBCL from our study can be used for resource allocation and 
health policy design. The phase specific costs of care over 3 years for DLBCL patients can also 
be used in cost-effectiveness analyses of interventions for disease prevention. 
4.7 Conclusions 
 DLBCL patients had substantially higher total costs of care than Medicare beneficiaries 
without cancer, which was primarily due to the treatments of chemo-immunotherapy and stem 
cell transplant. However, the cost of all chronic conditions was only moderately higher among 
DLBCL patients, and it varied depending on the specific chronic condition. The cost of heart 
conditions was higher while the cost of other chronic conditions was either lower or similar to 
non-cancer patients. Cardiotoxicity of DLBCL treatment may have increased the cost of heart 
conditions among DLBCL patients. It is important to adjust the bundled payments of DLBCL 
care for the cost of heart conditions. Even though risks for other conditions were increased in 
DLBCL patients, the cost was lower, indicating they might be receiving suboptimal care for 
other common chronic conditions. The quality of care for chronic conditions might need to be 
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improved for DLBCL patients. Future studies are suggested to investigate the impact of other 
common cancers such as breast, colorectal, and prostate cancer on the costs and quality of care 
for chronic conditions. Further, the long-term cost effectiveness of increasing chronic disease 
management among cancer patients needs to be examined. 
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Figure 4.1 Change in Cost of Heart Conditions and Cost of All Chronic Conditions among Medicare Beneficiaries 
with Diffuse Large B-Cell Lymphoma (DLBCL) and Beneficiaries without Cancer (2002-2013). 
 
Cost of all chronic conditions included inpatient, outpatient, and home health costs for arthritis, asthma/chronic 
obstructive pulmonary disease, any heart condition, any mental illness, diabetes, hypertension, hyperlipidemia, and 
osteoporosis. The study period of 3 years was categorized in 6 months’ intervals (t1-t6). The pre-index phase (t1, t2) 
was 12 months before DLBCL diagnosis and post-index phase (t3, t4, t5, t6) was 24 months after diagnosis.      
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Table 4.1 Description of Mean Total Cost and Cost of Chronic Conditions among 
Medicare Beneficiaries with Diffuse Large B-Cell Lymphoma (DLBCL) during 12 
Months after Cancer Diagnosis (2002-2013).  
 
n Total Cost, $ Sig. Chronic Cost, $ Sig. 
 
Total      5,455  80,220.9 
 
3,099.7 
 Sex 
  
* 
 
+ 
 
Female      3,029       79,598.4  
 
           2,839.3  
 
 
Male      2,426       80,998.2  
 
           3,424.9  
 Age (years) 
  
*** 
 
*** 
 
66-69      1,071       81,471.2  
 
           2,640.7  
 
 
70-74      1,374       83,406.9  
 
           2,392.9  
 
 
75-79      1,373       84,834.4  
 
           3,772.4  
 
 
>80      1,637       72,859.5  
 
           3,429.1  
 Race 
    
+ 
 
White      4,796       80,041.0  
 
           3,056.8  
 
 
African American         190       80,109.6  
 
           4,677.5  
 
 
Hispanic         120       88,400.9  
 
           3,477.5  
 
 
Others         349       79,942.3  
 
           2,699.5  
 Marital status 
  
*** 
  
 
Married      3,123       81,655.5  
 
           3,000.8  
 
 
Separated/Divorced/ 
Widowed      1,660       78,622.8  
 
           3,361.7  
 
 
Unmarried         372       85,446.4  
 
           3,483.6  
 Region 
  
*** 
 
*** 
 
North Central         720       77,346.3  
 
           3,306.8  
 
 
Northeast      1,113       87,656.8  
 
           4,134.9  
 
 
South      1,267       75,401.1  
 
           2,825.0  
 
 
West      2,355       80,178.7  
 
           2,694.9  
 Rurality 
  
*** 
 
*** 
 
Rural         115       68,590.1  
 
           2,658.9  
 
 
Urban         815       74,707.2  
 
           2,657.0  
 
 
Metro      4,525       81,509.6  
 
           3,190.6  
 Dual eligibility 
  
+ 
 
*** 
 
Yes         294       86,246.1  
 
           5,056.7  
 
 
No      5,161       79,877.7  
 
           2,988.2  
 Any heart condition 
  
*** 
 
*** 
 
Yes      3,537       88,840.2  
 
           4,395.3  
 
 
No      1,918       64,326.2  
 
              710.4  
 Asthma/COPD 
  
*** 
 
*** 
 
Yes      1,662       92,341.2  
 
           4,421.3  
 
 
No      3,793       74,910.2  
 
           2,520.6  
 Depression/Anxiety 
  
*** 
 
*** 
 
Yes      1,139       97,098.7  
 
           4,458.4  
 
 
No      4,316       75,766.9  
 
           2,741.1  
 Arthritis 
  
*** 
 
*** 
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Yes      1,750       87,501.7  
 
           4,208.0  
 
 
No      3,705       76,782.0  
 
           2,576.2  
 Diabetes 
  
*** 
 
*** 
 
Yes      1,942       88,311.7  
 
           4,626.8  
 
 
No      3,513       75,748.4  
 
           2,255.5  
 Tobacco use 
    
*** 
 
Yes         318       84,874.1  
 
           4,424.5  
 
 
No      5,137       79,932.9  
 
           3,017.7  
 DLBCL stage 
  
*** 
  
 
Stage I      1,813       72,724.4  
 
           2,964.0  
 
 
Stage II      1,066       82,795.0  
 
           3,249.3  
 
 
Stage III         812       83,118.8  
 
           3,033.1  
 
 
Stage IV      1,391       89,974.9  
 
           3,123.6  
 Chemo-immuno therapy 
  
*** 
 
** 
 
Yes      5,007       84,677.5  
 
           3,099.1  
 
 
No         448       30,412.9  
 
           3,106.2  
 Radiotherapy 
  
*** 
  
 
Yes      1,629       77,184.5  
 
           2,810.7  
 
 
No      3,826       81,513.8  
 
           3,222.8  
 Stem cell transplant 
  
*** 
  
 
Yes      3,479       82,594.2  
 
           3,090.2  
 
 
No      1,976       76,042.6  
 
           3,116.4  
 Primary care shortage 
area      
 
Part county      2,748       81,028.2  
 
           3,130.3  
 
 
Whole county      1,848       80,122.6  
 
           2,949.1  
 
 
No shortage         859       77,850.3  
 
           3,325.6  
 Note. Based on 5,455 Medicare beneficiaries with Diffuse Large B-Cell Lymphoma (DLBCL) > 66 years of age 
who resided in Surveillance, Epidemiology, and End Results program (SEER) areas. Total cost included all 
inpatient, outpatient, home health agency, and durable medical equipment costs. Cost of chronic conditions included 
inpatient, outpatient, and home health agency costs for arthritis, asthma/COPD, any heart condition, any mental 
illness, diabetes, hypertension, hyperlipidemia, and osteoporosis. All costs were adjusted to 2013 constant dollars. 
Significance values (Sig.) were derived from Kruskal-Wallis tests. 
COPD: Chronic Obstructive Pulmonary Disease. 
***p<.001 **.001< p<.01 *.01< p<.05 +.05<p<.1  
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Table 4.2 Differences in Total Cost and Cost of 
Chronic Conditions between Medicare Beneficiaries 
with Diffuse Large B-Cell Lymphoma (DLBCL) and 
Beneficiaries without Cancer (2002-2013).  
 
Total cost, $  
Time DLBCL No Cancer Net Cost Sig. 
t1 3,406.6 2,937.8 468.8 *** 
t2 5,123.4 3,701.5 1,421.9  
t3 64,228.9 3,482.8 60,746.1 
 t4 15,992.1 3,236.1 12,756.0 
 t5 10,586.1 3,519.7 7,066.4 
 t6 10,543.6 3,928.8 6,614.8 
 
 
Cost of chronic conditions, $ Sig. 
 
DLBCL No Cancer Net Cost *** 
t1 1,029.2 894.2 135.0 
 t2 1,084.7 1,187.3 -102.7 
 t3 1,765.7 997.4 768.3 
 t4 1,334.0 1,012.9 321.1 
 t5 1,232.8 1,018.8 214.1 
 t6 1,286.5 1,123.3 163.1 
 Note. Based on 5,455 Medicare beneficiaries with Diffuse Large B-Cell Lymphoma and 14,770 beneficiaries 
without cancer who were >66 years of age and resided in Surveillance, Epidemiology, and End Results program 
(SEER) areas. Total cost included all inpatient, outpatient, home health agency, and durable medical equipment 
costs. Cost of chronic conditions included inpatient, outpatient, and home health agency costs for arthritis, 
asthma/COPD, any heart condition, any mental illness, diabetes, hypertension, hyperlipidemia, and osteoporosis. All 
costs were adjusted to 2013 constant dollars. The study period of 3 years was categorized in 6 months’ intervals 
(pre-index: t1, t2 and post-index: t3, t4, t5, t6). Significance values (Sig.) were derived from Friedman's tests. 
***p<.001  
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Table 4.3 Description of Cost of Common Chronic 
Conditions among Medicare Beneficiaries with Diffuse 
Large B-Cell Lymphoma (DLBCL) and Beneficiaries 
without Cancer (2002-2013).    
Time DLBCL No Cancer Net Cost, $ Sig. 
 
Heart conditions, $ 
 
*** 
t1 576.7 428.4 148.3  
t2 635.1 698.8 -63.7 
 t3 1,164.8 500.9 663.9 
 t4 814.7 496.0 318.7 
 t5 743.5 504.7 238.8 
 t6 794.0 562.6 231.3 
 
 
Diabetes, $ 
  
*** 
t1 71.2 79.6 -8.3 
 t2 67.0 73.0 -5.9 
 t3 190.9 92.2 98.7 
 t4 123.1 86.8 36.3 
 t5 91.1 86.7 4.4 
 t6 92.6 97.6 -5.0 
 
 
Arthritis, $ 
   t1 205.9 177.7 28.3 
 t2 192.8 196.8 -4.0 
 t3 45.6 158.0 -112.3 
 t4 140.4 181.0 -40.5 
 t5 157.4 161.0 -3.6 
 t6 147.0 176.4 -29.5 
 
 
Hypertension, $ 
 
*** 
t1 67.3 85.1 -17.8 
 t2 81.6 87.4 -5.8 
 t3 149.6 106.0 43.7 
 t4 95.2 95.2 0.1 
 t5 76.7 91.4 -14.7 
 t6 96.2 105.0 -8.8 
 
 
Asthma/COPD, $ 
 
*** 
t1 28.77 38.54 -9.77 
 t2 43.23 37.22 6.01 
 t3 116.27 51.88 64.39 
 t4 56.16 60.73 -4.57 
 t5 57.43 59.96 -2.53 
 t6 62.10 63.88 -1.78 
 
 
Mental Illness, $ 
 
*** 
t1 46.25 55.24 -8.99 
 t2 28.64 65.52 -36.88 
 t3 66.68 56.88 9.80 
 t4 74.62 62.81 11.81 
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t5 71.94 82.52 -10.58 
 t6 61.45 81.31 -19.86 
 
 
Hyperlipidemia, $ 
  t1 26.00 23.57 2.43 
 t2 27.35 22.25 5.10 
 t3 15.70 24.24 -8.54 
 t4 19.69 23.81 -4.12 
 t5 22.74 23.88 -1.14 
 t6 23.23 25.70 -2.47 
 
 
Osteoporosis, $ 
  t1 7.08 6.24 0.84 
 t2 9.00 6.43 2.57 
 t3 16.03 7.34 8.69 
 t4 10.13 6.65 3.48 
 t5 12.11 8.67 3.44 
 t6 9.98 10.85 -0.87 
 Note. Based on 5,455 Medicare beneficiaries with Diffuse Large B-Cell Lymphoma and 14,770 beneficiaries with 
no cancer who were >66 years of age and resided in SEER areas. The cost of chronic conditions included inpatient, 
outpatient, and home health agency costs. All costs were adjusted to 2013 constant dollars. The study period of 3 
years was categorized in 6 months’ intervals (pre-index: t1, t2 and post-index: t3, t4, t5, t6). Significance values 
(Sig.) were derived from Friedman's tests. COPD: Chronic Obstructive Pulmonary Disease  
 ***p<.001. 
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Table 4.4 Parameter Estimates from Generalized Estimating 
Equations on Cost of Chronic Conditions among Medicare 
Beneficiaries with Diffuse Large B-Cell Lymphoma (DLBCL) as 
compared to Beneficiaries without Cancer (2002-2013).   
  
β SE Sig. 
Adjusted 
cost, $ 
Intercept 6.190 0.130 *** 489.4 
DLBCL 
     
 
Yes 0.182 0.035 *** 586.8 
 
No Cancer Ref. 
   Time 
    
 
Pre-Diagnosis 0.233 0.046 *** 617.7 
 
Treatment 0.217 0.043 *** 608.0 
 
Post-Treatment 0.178 0.046 *** 584.5 
 
Short Follow-up 0.151 0.045 *** 569.1 
 
Long Follow-up 0.233 0.044 *** 617.7 
 
Baseline Ref. 
   Age (Years) 
    
 
70-74 0.253 0.048 *** 630.5 
 
75-79 0.424 0.049 *** 747.7 
 
>80 0.582 0.045 *** 875.9 
 
66-69 Ref. 
   Sex 
     
 
Female -0.160 0.033 *** 418.6 
 
Male Ref. 
   Race  
     
 
Black  0.275 0.062 *** 644.5 
 
Hispanic 0.204 0.109 
 
600.0 
 
Others 0.014 0.064 
 
496.3 
 
White Ref. 
   Region 
     
 
North-Central -0.070 0.064 
 
456.7 
 
West -0.290 0.053 *** 367.3 
 
South -0.300 0.063 *** 364.1 
 
Northeast Ref. 
   Rurality 
     
 
Urban 0.142 0.099 
 
564.2 
 
Metro 0.190 0.102 
 
591.8 
 
Rural Ref. 
   Tobacco use 
    
 
Yes 1.180 0.069 *** 1,590.7 
 
No Ref. 
   County% Blacks 
    
 
4.43 0.017 0.053 
 
497.8 
 
9.88 0.167 0.061 ** 578.1 
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30.60 0.108 0.067 
 
545.2 
 
1.21 Ref. 
   County% FQHC 
    
 
0.36 -0.130 0.057 * 429.7 
 
0.94 -0.080 0.058 
 
449.8 
 
3.84 -0.100 0.055 
 
444.0 
 
0.01 Ref. 
   Primary care shortage area 
    
 
Part county 0.071 0.052 
 
525.6 
 
Whole county 0.128 0.057 * 556.3 
 
No shortage Ref. 
   County average travel time 
    
 
24.09 0.027 0.049 
 
502.6 
 
27.42 0.054 0.051 
 
516.4 
 
30.95 0.138 0.055 * 561.9 
 
19.62 Ref. 
   County% Less Than High 
School Education 
    
 
12.23 0.086 0.050 
 
533.3 
 
16.24 0.287 0.050 *** 652.1 
 
24.98 0.284 0.055 *** 649.9 
 
8.41 Ref. 
   Note. Based on 5,455 Medicare beneficiaries with Diffuse Large B-Cell Lymphoma and 14,770 beneficiaries 
without any cancer > 66 years of age who resided in SEER areas. FQHC: Federal Qualified Health Center; SE: 
standard errors; Sig: significance level. The adjusted cost of chronic conditions was derived from Generalized 
Estimating Equations with gamma distribution and log link. All costs were adjusted to 2013 constant dollars. 
***p<.001 **.001< p<.01 *.01< p<.05 
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Appendix 4.1 Description of One-Year Total Cost and Cost of Chronic 
Conditions among Medicare Beneficiaries >66 Years of Age without Cancer 
(2002-2013).  
 
n   Total Cost, $  sig 
 Total Chronic 
Cost, $  sig 
 
Total 14,770 6,718.8 
 
2,010.3 
 Sex 
  
*** 
 
*** 
 
Female 9,479 6,939.5 
 
2,018.9 
 
 
Male 5,291 6,323.5 
 
1,994.8 
 Age (years) 
  
*** 
 
*** 
 
66-69 4,452 5,078.1 
 
1,523.0 
 
 
70-74 3,914 6,110.7 
 
1,985.1 
 
 
75-79 2,786 7,396.4 
 
2,140.1 
 
 
>80 3,618 8,873.9 
 
2,537.1 
 Race 
  
+ 
 
*** 
 
White 11,885 6,577.0 
 
1,908.1 
 
 
African American 1,217 8,643.5 
 
2,987.5 
 
 
Hispanic 379 8,211.9 
 
2,841.0 
 
 
Others 1,289 5,769.9 
 
1,785.5 
 Region 
  
*** 
 
*** 
 
North Central 1,752 7,095.8 
 
2,127.7 
 
 
Northeast 2,885 7,091.6 
 
2,358.9 
 
 
South 3,779 6,189.2 
 
1,919.6 
 
 
West 6,354 6,760.6 
 
1,873.5 
 Rurality 
  
*** 
 
*** 
 
Rural 320 6,391.9 
 
1,541.0 
 
 
Urban 2,278 6,324.7 
 
1,887.1 
 
 
Metro 12,172 6,801.2 
 
2,045.7 
 Any heart condition 
  
*** 
 
*** 
 
Yes 5,749 12,027.2 
 
4,067.9 
 
 
No 9,021 3,335.8 
 
699.0 
 Asthma/COPD 
  
*** 
 
*** 
 
Yes 2,734 12,476.6 
 
3,965.8 
 
 
No 12,036 5,410.9 
 
1,566.1 
 Depression/Anxiety 
  
*** 
 
*** 
 
Yes 1,913 14,617.1 
 
3,814.5 
 
 
No 12,857 5,543.6 
 
1,741.8 
 Arthritis 
  
*** 
 
*** 
 
Yes 4,372 10,874.3 
 
3,497.9 
 
 
No 10,398 4,971.6 
 
1,384.8 
 Diabetes 
  
*** 
 
*** 
 
Yes 4,845 9,443.0 
 
2,959.6 
 
 
No 9,925 5,389.0 
 
1,546.8 
 Tobacco use 
  
*** 
 
*** 
 
Yes 464 13,312.3 
 
4,812.4 
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No 14,306 6,505.0 
 
1,919.4 
 Primary care shortage 
area      
 
Part county 7,094 6,514.0 
 
1,997.9 
 
 
Whole county 5,511 7,185.0 
 
2,115.3 
 
 
No shortage 2,165 6,203.2 
 
1,783.5 
 Note. Based on 14,770 Medicare beneficiaries with no cancer > 66 years of age who resided in Surveillance, 
Epidemiology, and End Results program (SEER) areas. Total cost included all inpatient, outpatient, home health 
agency, and durable medical equipment costs. Cost of chronic conditions included inpatient, outpatient, and home 
health agency costs for arthritis, asthma/COPD, any heart condition, any mental illness, diabetes, hypertension, 
hyperlipidemia, and osteoporosis. All costs were adjusted to 2013 constant dollars. Significance values (Sig.) were 
derived from Kruskal-Wallis tests. 
COPD: Chronic Obstructive Pulmonary Disease. 
***p<.001 **.001< p<.01 *.01< p<.05 +.05<p<.1   
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Appendix 4.2 Parameter Estimates from Generalized Estimating 
Equations on Cost of Chronic Conditions among Medicare 
Beneficiaries with Diffuse Large B-Cell Lymphoma > 66 Years of 
Age (2002-2013).   
  
β SE Sig. 
Adjusted 
cost, $ 
Intercept 6.650 0.234 *** 772.3 
Time 
    
 
Pre-Diagnosis 0.094 0.085 
 
848.5 
 
Treatment 0.545 0.078 *** 1,331.8 
 
Post-Treatment 0.340 0.085 *** 1,084.7 
 
Short Follow-up 0.261 0.086 ** 1,002.5 
 
Long Follow-up 0.295 0.084 *** 1,037.6 
 
Baseline Ref. 
   Age (Years) 
    
 
70-74 0.193 0.088 * 936.8 
 
75-79 0.377 0.086 *** 1,125.7 
 
>80 0.391 0.081 *** 1,142.1 
 
66-69 Ref. 
   Sex 
     
 
Female -0.280 0.055 *** 585.2 
 
Male Ref. 
   Race  
     
 
African American 0.389 0.135 ** 1,139.0 
 
Hispanic -0.060 0.191 
 
730.5 
 
Others 0.072 0.122 
 
830.3 
 
White Ref. 
   Region 
     
 
North-Central -0.090 0.103 
 
706.7 
 
West -0.360 0.080 *** 537.9 
 
South -0.270 0.085 ** 591.9 
 
Northeast Ref. 
   Rurality 
     
 
Urban 0.218 0.191 
 
960.7 
 
Metro 0.318 0.185 
 
1,061.2 
 
Rural Ref. 
   
Medicaid Dual Eligible  
    
 
Yes 0.579 0.109 *** 1,377.3 
 
No Ref. 
   
DLBCL stage 
    
 
Stage II -0.100 0.076 
 
696.0 
 
Stage III -0.060 0.082 
 
726.6 
 
Stage IV 0.047 0.073 
 
809.4 
 
Stage I Ref. 
   Tobacco use 
    
 
Yes 0.884 0.119 *** 1,870.2 
 
No Ref. 
   Chemo-immuno therapy 
    
 
Yes 0.032 0.110 
 
797.3 
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No Ref. 
   Radiotherapy 
    
 
Yes -0.120 0.059 * 685.4 
 
No Ref. 
   
Stem cell transplant 
    
 
Yes -0.050 0.057 
 
734.7 
 
No Ref. 
   Note. Based on 5,455 Medicare beneficiaries with Diffuse Large B-Cell Lymphoma > 66 years of age who resided 
in SEER areas. FQHC: Federal Qualified Health Center; SE: standard errors; Sig: significance level. The adjusted 
cost of chronic conditions was derived from Generalized Estimating Equations with gamma distribution and log 
link. All costs were adjusted to 2013 constant dollars. ***p<.001 **.001< p<.01 *.01< p<.05 
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Chapter 5: Discussion 
 
5.1 Results Summary and Discussion 
 The current study investigated the impact of newly diagnosed DLBCL on primary care 
and costs of care among elderly patients with DLBCL as compared to Medicare beneficiaries 
without cancer. Owing to the dearth of research on the impact of DLBCL on primary care and 
costs, we conducted this study to fill a critical knowledge gap and inform interventions for early 
disease prevention and chronic disease management among elderly patients with DLBCL. 
Specifically, our study examined the impact of newly diagnosed DLBCL on visits to PCPs and 
other medical specialists and costs of common chronic conditions before DLBCL diagnosis, 
during DLBCL treatment, and at follow-up periods as compared to Medicare beneficiaries 
without cancer. The study also analyzed the receipt of mammography and bone mineral density 
testing (BDT) by women with DLBCL during two years after DLBCL diagnosis as compared to 
women without cancer. We used a comprehensive Social Ecological Model (SEM) to examine 
individual as well as societal factors that may play a role in the care of DLBCL patients.1,2  
 One of the main goals of the study was to understand how having a DLBCL diagnosis 
influences a patient’s utilization of primary care services in comparison to patients without 
cancer. DLBCL patients had more visits to PCPs and some specialists as compared to those 
without any cancer, even after adjusting for intra-personal, inter-personal, healthcare system, and 
community factors. Surprisingly, even though DLBCL patients had more PCP visits, the rates of 
mammography and BDT were similar between female DLBCL and non-cancer patients. After 
controlling for PCP visits, female DLBCL patients were less likely to receive either 
mammography or BDT as compared to women without cancer, which is concerning as female 
DLBCL patients are at a greater risk of breast cancer and osteoporosis. The prioritization of 
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acute cancer care might have resulted in suboptimal preventive screenings in DLBCL patients. 
Another important reason for the less-than-ideal receipt of preventive services among DLBCL 
patients is limited provider and patient time. The providers face the difficulty of integrating 
many screenings recommended by the USPSTF along with the competing demands of intensive 
DLBCL treatment.3 The patients are also engaged with the tremendous increase in number of 
diagnostic and therapeutic approaches for DLBCL. Further, 80-100% of cancer patients report 
cancer-related fatigue in addition to the treatment side effects.4 Amid the burden of DLBCL 
treatment and its effects, patients may not adhere to guidelines for preventive services. The 
providers and patients must choose which preventive services will deliver the largest 
improvement in quality of life and overall survival. Some previous studies have ranked the 
USPSTF recommended preventive services with regard to their health impact and cost-
effectiveness.5 Although all preventive services are important and should be provided, giving 
such information on the relative importance of preventive services to providers and patients can 
assist in deciding where to focus their prevention efforts.  
 There is also a need for individualized risk-based preventive care of patient based on the 
treatment received, age of patient, and risk of developing a disease. We did not find a significant 
relationship of the type of DLBCL treatment such as radiotherapy and stem cell transplant with 
mammography and BDT. Increasing mammography screening of patients receiving 
chemotherapy and more BDT of those receiving stem cell transplant can increase the early 
detection of breast cancer and osteoporosis and hence, reduce the morbidity and mortality from 
these conditions. Further, women between 70-74 years of age were less likely to have 
mammography and women above 70 years of age were less likely to receive BDT than women 
between 66-74 years of age. Continued mammography screening for women aged 70-74 years 
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and BDT among women above 70 years of age is also needed, as recommended by the US 
Preventive Services Task Force (USPSTF) guidelines. Currently, there is a lack of clinical 
guidelines for preventive care of patients with different types of cancers and treatments. Future 
development and refinement of such guidelines can further assist in prioritization of specific 
preventive services depending on the risk of a particular cancer patient. 
 Our second goal was to examine the differences in visits to provider type and utilization 
of care for different types of chronic diseases among DLBCL patients over the cancer care 
trajectory. Although DLBCL diagnosis resulted in more visits to PCPs and some specialists and 
increased the total cost of chronic conditions, the impact of DLBCL varied as a function of the 
type of provider specialty and the type of chronic disease. For instance, visits to cardiologists, 
pulmonologists, and endocrinologists and cost of cardiac conditions increased during the 
treatment period. The significant increase in visits to endocrinologists and cost of cardiac 
conditions may be due to chemotherapy with Doxorubicin among DLBCL patients, which can 
cause significant cardiotoxicity including the development of congestive heart failure and 
cardiomyopathy in lymphoma patients.6,7 Interventions to reduce the long terms costs of DLBCL 
can be more effective by increasing the preventive care for heart conditions before and during 
treatment, especially for patients with pre-existing cardiac illnesses. Some primary prevention 
measures for cardiac illnesses include the use of biomarkers and imaging studies for early 
detection and administration of dexrazoxane for preventive treatment.62 Further, for the 
‘Oncology Care Model’ with bundled payments for cancer patients,8 policy makers and 
researchers should consider the cost of heart conditions while setting benchmarks for the 
reimbursements of care for DLBCL.  
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 Although the utilization of care for cardiac conditions increased, the visits to 
rheumatologists and mental health specialists decreased during treatment and follow-up periods. 
Further, the cost of arthritis decreased from DLBCL diagnosis to treatment and follow-up 
periods. DLBCL patients also had lower costs of other conditions such as hypertension, 
asthma/COPD, mental illness, and diabetes during the baseline and follow-up periods. There was 
no significant difference in the cost of hyperlipidemia and osteoporosis as compared to non-
cancer patients. These findings may reflect lower quality of care for these chronic conditions as 
found in some previous studies.9,10 One possible explanation is that patients might be engaged 
with the sudden increase in treatments for DLBCL and may not have enough time or energy to 
visit providers for chronic conditions. Currently there is a lack of studies examining this 
phenomenon among patients with newly diagnosed cancer. Future studies might shed further 
light on the reasons for poorer quality of care for chronic conditions among cancer patients. 
Also, the diagnosis and treatment of DLBCL can lead to an increase in mental health conditions 
such as anxiety, depression, post-traumatic stress disorder, and poorer health status.11-13 Even 
though DLBCL patients in our study had an increased diagnosis of mental health conditions over 
treatment and follow-up periods, their visits to mental health providers did not change. It is 
critical to screen elderly DLBCL patients for mental health conditions during and after DLBCL 
treatment and to refer suitable patients to mental health providers when necessary. Similarly, 
DLBCL patients are at a greater risk of osteoporosis and fractures. Given the low rate of BDT 
among elderly women, clinicians and other healthcare providers may consider using an 
osteoporosis risk assessment tool14 to analyze the absolute fracture risk of women with DLBCL 
and to provide BDT and appropriate osteoporosis treatments. Further research on the impact of 
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DLBCL on quality of care of these chronic conditions and their association with overall survival 
is warranted. 
 In addition to our two main study goals, we also explored the functionality of an 
ecological model to help us understand the impact of DLBCL over the cancer care trajectory. 
The use of an ecological model helped us identify additional environmental factors, which were 
significantly related to the care of DLBCL patients. The racial composition of county was a 
significant determinant of the visits to PCPs, as DLBCL patients living in counties with a higher 
percentage of African Americans had less PCP visits. Further, the racial composition of county 
had a significant interaction with the patient’s race on the total costs of chronic conditions. 
African Americans living in counties with higher prevalence of African Americans had higher 
total cost of chronic conditions. Those living in the South or West regions as compared to 
Northeast had more PCP visits but less total cost of chronic conditions. Other significant societal 
factors included the level of education and health insurance in the county. Medicare beneficiaries 
with DLBCL living in counties with a lower education level had more PCP visits and higher total 
cost of chronic conditions. Further, DLBCL patients living in counties with less health insurance 
had fewer PCP visits. With respect to preventive care, DLBCL patients living in counties with 
more travel time were less likely to have mammography and those living in counties with higher 
prevalence of Hispanics were more likely to have BDT. These findings indicate the importance 
of policy changes aimed at environmental and organizational factors in addition to individual 
level factors for improving care and reducing costs among DLBCL patients. Given the lack of 
environmental and organizational variables in many existing studies, it would be valuable for 
more studies to analyze the contribution of environmental factors to the understanding of 
primary care and costs among cancer patients.  
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5.2 Study Limitations 
 Our study findings should be interpreted in the context of some limitations. First, the 
study sample included elderly individuals enrolled in fee-for-service Medicare and without 
Health Maintenance Organization (HMO) enrollment. Hence, the study findings may not be 
applicable to younger patients, those enrolled in managed care or commercial insurance plans, 
and those residing in non- Surveillance, Epidemiology, and End Results Program (SEER) 
regions. In addition, for the second aim, our study was restricted to elderly women with DLBCL 
between 65-74 years of age for mammography screening and above 65 years of age for BDT. 
Therefore, the findings from aim 2 cannot be generalized to men and younger women. We used 
the Health Care Financing Administration (HCFA) codes to determine the physician specialty in 
this study which might underestimate the provider specialties in the Medicare claims. Further, 
due to non-enrollment in Medicare Part D by most of our study sample, we could not include the 
costs of prescription drugs in the costs of chronic conditions in our study.  
5.3 Study Strengths 
 Despite some limitations, the current study contributed to the nascent literature on the 
impact of DLBCL on visits to different provider specialties, preventive care, and the costs of 
chronic conditions among elderly individuals with newly diagnosed DLBCL as compared to 
Medicare beneficiaries without cancer. Our study examined the visits to other medical specialists 
over a three-year time period spanning the cancer diagnosis, treatment, and follow-up periods, 
which had not been examined in the literature previously. We used the SEER-Medicare database, 
which is a nationally representative data to examine the care of elderly patients with newly 
diagnosed cancer. Since Medicare is the primary insurance payer for individuals above 65 years 
of age, SEER-Medicare dataset provides the most complete information on the use and cost of 
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health services by beneficiaries with cancer. Also, a comprehensive SEM framework analyzed 
the association of various personal and contextual factors with primary care and costs among 
elderly DLBCL patients. Other strengths of this study include a robust study design with Inverse 
Probability Treatment Weights (IPTW) adjusted analyses to reduce observed selection bias, a 
non-cancer comparison group, and time varying diagnosis of chronic conditions. The direct 
medical cost estimates of specific chronic conditions and DLBCL from our study can be used for 
resource allocation and health policy design. The phase specific costs of care over 3 years for 
DLBCL patients can also be used in cost-effectiveness analyses of interventions for disease 
prevention. 
5.4 Conclusions and Research Implications 
 Elderly Medicare beneficiaries with DLBCL were more likely to visit PCPs, 
cardiologists, pulmonologists, and endocrinologists than non-cancer patients. Treatment adverse 
effects and more frequent contact with the healthcare system may have led to an increased 
diagnosis of other chronic conditions, which partially explained more visits to PCPs and some 
specialists. Interventions to improve care-coordination among PCPs and specialists may need to 
target the treatment period when coordination is most vulnerable. However, an increased 
diagnosis of mental health conditions and other chronic conditions did not result in increased 
visits to mental health specialists and other corresponding provider specialties. Elderly DLBCL 
patients should be screened for mental health conditions and referred to mental health specialists 
when necessary. Patients with pre-existing conditions and those receiving chemo-
immunotherapy and stem cell transplant need extra attention for the care of chronic conditions. 
Further research and interventions to improve the quality of care for these conditions among 
patients with DLBCL are warranted.  
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Even though DLBCL patients had more PCP visits, female DLBCL patients were less 
likely to receive mammography and BDT than women without cancer. Interventions to increase 
the recommendations for mammography screening and BDT among women with DLBCL are 
needed. Rates of mammography should especially be increased for elderly women receiving 
chemo-immunotherapy and BDT for those receiving stem cell transplant. Risk assessment tools 
for osteoporosis can further help in targeting the use of BDT and treatment of osteoporosis in 
DLBCL patients. Further, due to the low rate of preventive care among Medicare beneficiaries, 
future studies should investigate the impact of newly diagnosed cancer on the receipt of other 
preventive services recommended by the USPSTF. With respect to the cost of care, DLBCL 
patients had markedly higher total costs due to cancer treatment than Medicare beneficiaries 
without cancer. The cost of all chronic conditions was only moderately higher among DLBCL 
patients, and it varied for different types of chronic conditions. The cost of heart conditions was 
higher while the cost of other common chronic conditions was lower among DLBCL patients 
than those without cancer. Personalized medicine, through use of biomarkers and imaging 
studies, for early detection and preventive drug therapies for treatment of cardiac illnesses may 
reduce the cost of DLBCL patients. It is also critical to examine the long-term cost-effectiveness 
of increasing chronic disease management in patients with cancer.  
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